Olaparib (KU0059436) | PARP Inhibitor

Type	HazMat fee for 500 gram (Estimated)
Excepted Quantity	USD 0.00
Limited Quantity	USD 15-60
Inaccessible (Haz class 6.1), Domestic	USD 80+
Inaccessible (Haz class 6.1), International	USD 150+
Accessible (Haz class 3, 4, 5 or 8), Domestic	USD 100+
Accessible (Haz class 3, 4, 5 or 8), International	USD 200+

Size	Price	VIP Price	US Stock	Global Stock	In Stock
{[ item.pr_size ]}		Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}			Login	- +	Inquiry

NCT02571725	Ovarian Cancer ... More >> Fallopian Tube Cancer Peritoneal Neoplasms Less <<	Phase 1 Phase 2	Recruiting	February 2022	United States, Florida ... More >> Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Eleni Rokakis, BSN, RN 813-745-3593 Eleni.Rokakis@moffitt.org United States, New Mexico Southwest Gynecologic Oncology Associates Recruiting Albuquerque, New Mexico, United States, 87106 Contact: Karen Finkelstein, MD 505-843-7813 University of New Mexico Comprehensive Cancer Center Recruiting Albuquerque, New Mexico, United States, 87131 Contact: Valerie Parks, RN 505-925-0390 vparks@salud.unm.edu Principal Investigator: Sarah F Adams, MD United States, Ohio The Ohio State University Recruiting Columbus, Ohio, United States, 43210 Contact: David M O'Malley, MD 614-685-6411 Contact: Molly Myers 614-685-6411 molly.myers@osumc.edu United States, Virginia University of Virginia Cancer Center Recruiting Charlottesville, Virginia, United States, 22903 Contact: Anne Gabel 434-982-6657 am7bd@virginia.edu Less <<
NCT03579784	Advanced Gastric Cancer	Phase 2	Recruiting	April 30, 2020	Korea, Republic of ... More >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of, 110-744 Contact: Do-Youn Oh, MD, PhD 82-2-2072-0701 ohdoyoun@snu.ac.kr Less <<
NCT01972217	Metastatic Castration-resistan... More >>t Prostate Cancer Less <<	Phase 2	Active, not recruiting	December 31, 2018	-
NCT02893917	Castration Levels of Testoster... More >>one Castration-Resistant Prostate Carcinoma Metastatic Prostate Carcinoma Prostate Adenocarcinoma With Focal Neuroendocrine Differentiation Prostate Carcinoma Metastatic in the Bone Prostate Small Cell Carcinoma PSA Progression Stage IV Prostate Adenocarcinoma AJCC v7 Less <<	Phase 2	Recruiting	-	United States, California ... More >> UC San Diego Moores Cancer Center Recruiting La Jolla, California, United States, 92093 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Rana R. McKay University of California Davis Comprehensive Cancer Center Recruiting Sacramento, California, United States, 95817 Contact: Site Public Contact 916-734-3089 Principal Investigator: Mamta Parikh University of California San Diego Recruiting San Diego, California, United States, 92103 Contact: Site Public Contact 858-822-5354 cancercto@ucsd.edu Principal Investigator: Rana R. McKay United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital Recruiting New Haven, Connecticut, United States, 06510 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim Yale University Recruiting New Haven, Connecticut, United States, 06520 Contact: Site Public Contact 203-785-5702 canceranswers@yale.edu Principal Investigator: Joseph W. Kim United States, Florida Moffitt Cancer Center Recruiting Tampa, Florida, United States, 33612 Contact: Site Public Contact 800-456-7121 canceranswers@moffitt.org Principal Investigator: Jingsong Zhang United States, Massachusetts Massachusetts General Hospital Cancer Center Recruiting Boston, Massachusetts, United States, 02114 Contact: Site Public Contact 877-726-5130 Principal Investigator: Mary-Ellen Taplin Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Site Public Contact 888-823-5923 ctsucontact@westat.com Principal Investigator: Mary-Ellen Taplin Beth Israel Deaconess Medical Center Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 617-667-9925 Principal Investigator: Mary-Ellen Taplin Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Site Public Contact 877-442-3324 Principal Investigator: Mary-Ellen Taplin United States, Michigan Wayne State University/Karmanos Cancer Institute Recruiting Detroit, Michigan, United States, 48201 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan Weisberg Cancer Treatment Center Recruiting Farmington Hills, Michigan, United States, 48334 Contact: Site Public Contact 313-576-9790 ctoadmin@karmanos.org Principal Investigator: Ulka N. Vaishampayan United States, Ohio Ohio State University Comprehensive Cancer Center Recruiting Columbus, Ohio, United States, 43210 Contact: Site Public Contact 800-293-5066 Jamesline@osumc.edu Principal Investigator: J. P. Monk United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Recruiting Pittsburgh, Pennsylvania, United States, 15232 Contact: Site Public Contact 412-647-8073 Principal Investigator: Leonard J. Appleman United States, Tennessee Vanderbilt University/Ingram Cancer Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Site Public Contact 800-811-8480 Principal Investigator: David D. Chism United States, Virginia Virginia Commonwealth University/Massey Cancer Center Recruiting Richmond, Virginia, United States, 23298 Contact: Site Public Contact mwellons@vcu.edu Principal Investigator: Asit K. Paul Less <<
NCT03212742	Malignant Gliomas ... More >> Radiotherapy PARP Inhibitor Less <<	Phase 1 Phase 2	Recruiting	June 30, 2022	France ... More >> CHU Not yet recruiting Bordeaux, France Contact: Aymeri HUCHET, MD Principal Investigator: Aymeri HUCHET, MD Centre François Baclesse Recruiting Caen, France, 14076 Contact: Dinu STEFAN, MD 33 2 31 45 50 50 d.stefan@baclesse.unicancer.fr Contact: Jean-Michel GRELLARD Principal Investigator: Dinu STEFAN, MD Sub-Investigator: Julien GEFFRELOT, MD Sub-Investigator: Ioana HRAB, MD Centre léon Bérard Not yet recruiting Lyon, France Contact: Marie-Pierre SUNYACH, MD Principal Investigator: Marie-Pierre SUNYACH, MD Hôpitaux universitaires La Pitié Salpétrière - Charles Foix Not yet recruiting Paris, France Contact: Loic FEUVRET, MD Principal Investigator: Loic FEUVRET, MD Sub-Investigator: Florence LAIGLE-DONADEY, MD Sub-Investigator: Khe HOANG-XUAN, MD Sub-Investigator: Ahmed IBDAIH, Pr Institut Curie Not yet recruiting Paris, France Contact: Hamid MAMMAR, MD Principal Investigator: Hamid MAMMAR, MD Sub-Investigator: Laurence BOZEC LE MOAL, MD Sub-Investigator: Coraline DUBOT, MD Sub-Investigator: Patricia TRESCA, MD Sub-Investigator: Patricia MOISSON, MD Institut Claudius Regaud Not yet recruiting Toulouse, France Contact: Elisabeth MOYAL COHEN-JONATHAN, Pr Principal Investigator: Elisabeth MOYAL COHEN-JONATHAN, Pr Sub-Investigator: Ioana CARPUC, MD Sub-Investigator: Jean-Pierre DELORD, MD Sub-Investigator: Cécile GANDY, MD Sub-Investigator: Carlos Alberto GOMEZ-ROCA, MD Sub-Investigator: Anouchka MODESTO, MD Sub-Investigator: Thibaud VALENTIN, MD Less <<
NCT01972217	-		Active, not recruiting	-	-
NCT02000622	Breast Cancer Metastatic ... More >> BRCA 1 Gene Mutation BRCA 2 Gene Mutation Less <<	Phase 3	Active, not recruiting	December 31, 2019	-
NCT01460888	Carcinoma of the Oesophagus	Phase 1	Unknown	August 2018	United Kingdom ... More >> The Christie NHS Foundation Trust Not yet recruiting Manchester, United Kingdom, M20 4BX Principal Investigator: Hamid Shiekh, Dr Southampton General Hospital Recruiting Southampton, United Kingdom, SO16 6YD Contact: Andrew Jackson, MD +44(0)2380795386 Andrew.Jackson@uhs.nhs.uk Principal Investigator: Andrew Jackson, Dr Less <<
NCT03531840	Mesothelioma	Phase 2	Recruiting	December 1, 2020	United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Less <<
NCT02899728	Extensive Stage Lung Small Cel... More >>l Carcinoma Less <<	Phase 2	Suspended(Other - Pending prot... More >>ocol amendment) Less <<	April 7, 2020	United States, California ... More >> Los Angeles County-USC Medical Center Los Angeles, California, United States, 90033 USC / Norris Comprehensive Cancer Center Los Angeles, California, United States, 90033 Keck Medical Center of USC Pasadena Pasadena, California, United States, 91105 United States, Florida Mayo Clinic in Florida Jacksonville, Florida, United States, 32224-9980 Moffitt Cancer Center Tampa, Florida, United States, 33612 United States, Georgia Emory University Hospital Midtown Atlanta, Georgia, United States, 30308 Emory University Hospital/Winship Cancer Institute Atlanta, Georgia, United States, 30322 United States, Kentucky University of Kentucky/Markey Cancer Center Lexington, Kentucky, United States, 40536 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Minnesota Mayo Clinic Rochester, Minnesota, United States, 55905 United States, Missouri Siteman Cancer Center at West County Hospital Creve Coeur, Missouri, United States, 63141 Washington University School of Medicine Saint Louis, Missouri, United States, 63110 Siteman Cancer Center at Christian Hospital Saint Louis, Missouri, United States, 63136 Siteman Cancer Center at Saint Peters Hospital Saint Peters, Missouri, United States, 63376 United States, New York Laura and Isaac Perlmutter Cancer Center at NYU Langone New York, New York, United States, 10016 United States, Ohio Case Western Reserve University Cleveland, Ohio, United States, 44106 Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania Thomas Jefferson University Hospital Philadelphia, Pennsylvania, United States, 19107 University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Virginia University of Virginia Cancer Center Charlottesville, Virginia, United States, 22908 Virginia Commonwealth University/Massey Cancer Center Richmond, Virginia, United States, 23298 Less <<
NCT02000622	-		Active, not recruiting	-	-
NCT02882308	Squamous Cell Carcinoma of the... More >> Head and Neck Less <<	Phase 2	Recruiting	May 2019	Greece ... More >> Euromedica General Clinic of Thessaloniki Recruiting Thessaloníki, Thessaloniki, Greece, 54645 Contact: George Fountzilas, Prof.Emeritus 00302310683136 fountzil@auth.gr University Hospital "Attikon", 2nd Department of Internal Medicine, Division of Oncology Recruiting Athens, Greece, 12462 Contact: Diamanto Psyrri, MD,Ass.Prof 0030 2105831256 dp237@email.med.yale.edu Less <<
NCT02485990	Primary Peritoneal Carcinoma	Phase 1 Phase 2	Recruiting	September 2021	United States, Maryland ... More >> Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231 Contact: Maureen Berg, RN 443-287-6602 mberg1@jhmi.edu Less <<
NCT02769962	Solid Tumors ... More >>Small Cell Lung Carcinoma Carcinoma, Non-Small-Cell Lung Lung Neoplasms Small Cell Lung Cancer Lung Cancer Less <<	Phase 1 Phase 2	Recruiting	December 31, 2026	United States, Maryland ... More >> National Institutes of Health Clinical Center Recruiting Bethesda, Maryland, United States, 20892 Contact: For more information at the NIH Clinical Center contact National Cancer Institute Referral Office 888-624-1937 Less <<
NCT03575078	Lymphoma	Phase 1	Not yet recruiting	August 23, 2023	-
NCT03127215	Cancers With DNA Repair-Defici... More >>ency Less <<	Phase 2	Recruiting	March 31, 2021	Germany ... More >> National Center for Tumordiseases (NCT) Recruiting Heidelberg, Germany, 69120 Contact: R. Schlenk, MD +49622156 ext 6228 studienzentrale@nct-heidelberg.de Less <<
NCT03561870	Recurrent IDH ... More >> Mutant High Grade Glioma Less <<	Phase 2	Not yet recruiting	June 1, 2021	-
NCT03278717	Ovarian Cancer	Phase 3	Not yet recruiting	December 2023	-
NCT02822157	Ovarian Epithelial Cancer	Phase 2	Recruiting	May 2019	Belgium ... More >> UZLeuven Recruiting Leuven, Belgium Contact: Ignace Vergote +32 16 34 74 19 joke.deroover@uzleuven.be Less <<
NCT02684318	Advanced Cancer ... More >> Ovarian Cancer Endometrial Cancer Breast Cancer Less <<	Phase 1 Phase 2	Recruiting	October 2019	Spain ... More >> Hospital Reina Sofía Recruiting Córdoba, Andalucía, Spain, 14004 Contact: Maria Jesus Rubio, MD Hospital Marqués de Valdecilla Recruiting Santander, Cantabria, Spain, 39008 Contact: Ana de Juan Hospital Universitario Vall d'Hebron Recruiting Barcelona, Spain, 08035 Contact: Ana Oaknin, MD 0034934894158 opadros@vhio.net Principal Investigator: Ana Oaknin, MD Hospital Ramón y Cajal Recruiting Madrid, Spain, 28034 Contact: Eva Guerra, MD Hospital La Paz Recruiting Madrid, Spain, 28046 Contact: Andrés Redondo, MD Fundación Instituto Valenciano de Oncología Recruiting Valencia, Spain, 46009 Contact: Andrés Poveda, MD 0034961104647 apoveda@fivo.org Principal Investigator: Andrés Poveda, MD Less <<
NCT02340611	Ovarian Cancer	Phase 2	Completed	-	Canada, Ontario ... More >> Princess Margaret Cancer Centre Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT01874353	-		Active, not recruiting	-	-
NCT02418624	Breast Cancer ... More >> Ovarian Cancer Advanced Cancer Less <<	Phase 1	Unknown	May 2016	Netherlands ... More >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital Recruiting Amsterdam, Netherlands, 1066CX Contact: Regina Von Furstenberg 0031205127495 r.v.furstenberg@nki.nl Contact: Gwen Dackus, MD 0031205126965 g.dackus@nki.nl Principal Investigator: J.H.M. Schellens, MD, PhD Less <<
NCT02983799	Relapsed Ovarian Cancer, BRCA ... More >>Mutation, Platinum Sensitivity Less <<	Phase 2	Recruiting	May 21, 2020	-
NCT03682289	Clear Cell Renal Cell Carcinom... More >>a Locally Advance Pancreatic Ductal Adenocarcinoma Locally Advanced Malignant Solid Neoplasm Metastatic Malignant Solid Neoplasm Metastatic Renal Cell Carcinoma Metastatic Urothelial Carcinoma Pancreatic Ductal Adenocarcinoma Stage III Pancreatic Cancer AJCC v8 Stage III Renal Cell Cancer AJCC v8 Stage IV Pancreatic Cancer AJCC v8 Stage IV Renal Cell Cancer AJCC v8 Less <<	Phase 2	Not yet recruiting	March 19, 2023	United States, California ... More >> UCSF Medical Center-Mount Zion Not yet recruiting San Francisco, California, United States, 94115 Contact: Rahul R. Aggarwal 877-837-3222 Principal Investigator: Rahul R. Aggarwal, MD Less <<
NCT02755844	Recurrent Endometrial Cancer	Phase 1 Phase 2	Not yet recruiting	November 2019	France ... More >> Centre Hospitalier Lyon Sud Not yet recruiting Pierre Benite, France, 69495 Contact: Benoit YOU Contact: Marine DUPUIS Principal Investigator: Benoit YOU, MD Less <<
NCT02686008	Squamous Cell Carcinoma of the... More >> Head and Neck Less <<	PHASE1	WITHDRAWN	2025-07-19	-
NCT01874353	Platinum Sensitive ... More >> BRCA Mutated Relapsed Ovarian Cancer Following Complete or Partial Response to Platinum Based Chemotherapy Less <<	Phase 3	Active, not recruiting	June 2, 2021	-
NCT02392676	Platinum Sensitive Relapsed Ov... More >>arian Cancer Less <<	Phase 3	Withdrawn(Study is unlikely to... More >> be feasible given the evolving ovarian cancer landscape and alternative studies have the potential to meet future clinical demand.) Less <<	June 2019	-
NCT03579316	Recurrent Fallopian Tube Carci... More >>noma Recurrent Ovarian Carcinoma Recurrent Primary Peritoneal Carcinoma Less <<	Phase 2	Recruiting	March 31, 2019	United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 United States, Texas M D Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Robert L. Coleman 713-745-3357 Principal Investigator: Robert L. Coleman Less <<
NCT03317392	Castration Levels of Testoster... More >>one Castration-Resistant Prostate Carcinoma Metastatic Malignant Neoplasm in the Bone Prostate Adenocarcinoma PSA Progression Less <<	Phase 1 Phase 2	Not yet recruiting	April 30, 2020	-
NCT01813474	Cancer Advanc... More >>ed Solid Malignancies Less <<	Phase 1	Completed	-	Japan ... More >> Research Site Chuo-ku, Japan, 104-0045 Research Site Fukuoka-shi, Japan, 811-1395 Research Site Sapporo-shi, Japan, 003-0804 Less <<
NCT01900028	Solid Tumours	Phase 1	Completed	-	Belgium ... More >> Research Site Gent, Belgium, 9000 Research Site Gent, Belgium Research Site Leuven, Belgium, 3000 Research Site Leuven, Belgium Research Site Liege, Belgium, 4000 Research Site Liege, Belgium Denmark Research site Herlev, Denmark, 2730 Research Site København, Denmark, 2100 Netherlands Research Site Amsterdam, Netherlands, 1081 HV Research Site Maastricht, Netherlands, 6229 HX Research Site Nijmegen, Netherlands, 6525 GA United Kingdom Research Site London, United Kingdom Research Site Newcastle, United Kingdom, NE7 7DN Research Site Sutton, United Kingdom, SM2 5PT Less <<
NCT03012321	Prostate Cancer Metastatic Cas... More >>tration-Resistant Abnormal DNA Repair Metastatic Prostate Carcinoma Stage IV Prostate Cancer Less <<	Phase 2	Recruiting	January 2022	United States, California ... More >> City of Hope National Medical Center Active, not recruiting Duarte, California, United States, 91010 United States, Florida H. Lee Moffitt Cancer Center and Research Institute Recruiting Tampa, Florida, United States, 33612 Contact: Jingsong Zhang, MD 813-745-4673 Principal Investigator: Jingsong Zhang, MD United States, Illinois Northwestern Medicine Recruiting Chicago, Illinois, United States, 60611 Contact: Maha Hussain, MD, FACP, FASCO 312-695-6180 Principal Investigator: Maha Hussain, MD, FACP, FASCO Sub-Investigator: Alicia K. Morgans, MD, MPH Rush University Cancer Center Recruiting Chicago, Illinois, United States, 60612 Contact: Nicklas Pfanzelter, MD 312-942-5904 Principal Investigator: Nicklas Pfanzelter, MD University of Chicago Recruiting Chicago, Illinois, United States, 60637 Contact: Russell Szmulewitz, MD 773-702-7609 Principal Investigator: Russell Szmulewitz, MD Kellogg Cancer Center - NorthShore University Recruiting Evanston, Illinois, United States, 60201 Contact: Daniel Shevrin, MD 847-570-2515 Principal Investigator: Daniel Shevrin, MD United States, Indiana Indiana University/ Melvin and Bren Simon Cancer Center Recruiting Indianapolis, Indiana, United States, 46202 Contact: Roberto Pili, MD 317-948-8310 Principal Investigator: Roberto Pili, MD United States, Maryland Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Recruiting Baltimore, Maryland, United States, 21231 Contact: Emmanuel Antonarakis, MD 410-502-7528 Principal Investigator: Emmanuel Antonarakis, MD United States, Michigan University of Michigan Health System Recruiting Ann Arbor, Michigan, United States, 48109-5946 Contact: Todd Morgan, M.D. 734-647-8903 Sub-Investigator: Todd Morgan, M.D. Sub-Investigator: Zachery Reichert, M.D., Ph.D. Sub-Investigator: Arul Chinnaiyan, M.D., Ph.D. Sub-Investigator: Scott Tomlins, M.D., Ph.D. Karmanos Cancer Center Recruiting Detroit, Michigan, United States, 48201 Contact: Ulka Vaishampayan, MD 313-745-5111 Principal Investigator: Ulka Vaishampayan, MD United States, Minnesota Mayo Clinic Recruiting Rochester, Minnesota, United States, 55905 Contact: Manish Kohli, M.D. 507-538-3270 Principal Investigator: Manish Kohli, M.D. United States, Missouri Washington University School of Medicine Recruiting Saint Louis, Missouri, United States, 63110 Contact: Joel Picus, MD 314-747-9281 Principal Investigator: Joel Picus, MD United States, New Jersey Rutgers Cancer Institute of New Jersey Active, not recruiting New Brunswick, New Jersey, United States, 08903 United States, New York Weill Cornell Medical College Recruiting New York, New York, United States, 10065 Contact: Himisha Beltran, MD 646-962-2072 Principal Investigator: Himisha Beltran, MD United States, North Carolina University of North Carolina at Chapel Hill Recruiting Chapel Hill, North Carolina, United States, 27514 Contact: Young Whang, MD 919-966-4996 Principal Investigator: Young Whang, MD United States, Utah Huntsman Cancer Institute - University of Utah Recruiting Salt Lake City, Utah, United States, 84112 Contact: Neeraj Agarwal, MD 801-585-0100 Principal Investigator: Neeraj Agarwal, MD United States, Virginia University of Virginia Recruiting Charlottesville, Virginia, United States, 22903 Contact: Robert Dreicer, MD 434-924-9333 Principal Investigator: Robert Dreicer, MD Less <<
NCT03459846	Urinary Bladder Neoplasms	Phase 2	Recruiting	June 28, 2021	-
NCT03259503	Malignant Neoplasms Stated as ... More >>Primary Lymphoid Haematopoietic Lymphoma Less <<	Phase 1 Phase 2	Not yet recruiting	May 2019	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Not yet recruiting Houston, Texas, United States, 77030 Contact ynieto@mdanderson.org Less <<
NCT01813474	-		Completed	-	-
NCT02282020	Relapsed Ovarian Cancer, BRCA ... More >>Mutation, Platinum Sensitivity Less <<	Phase 3	Active, not recruiting	January 1, 2021	-
NCT03212274	Advanced Malignant Solid Neopl... More >>asm Glioblastoma IDH1 Gene Mutation IDH2 Gene Mutation Recurrent Cholangiocarcinoma Recurrent Glioma Recurrent Malignant Solid Neoplasm WHO Grade II Glioma WHO Grade III Glioma Less <<	Phase 2	Suspended(Other - null)	July 31, 2019	United States, California ... More >> University of California Davis Comprehensive Cancer Center Sacramento, California, United States, 95817 United States, Connecticut Smilow Cancer Center/Yale-New Haven Hospital New Haven, Connecticut, United States, 06510 Yale University New Haven, Connecticut, United States, 06520 United States, District of Columbia MedStar Georgetown University Hospital Washington, District of Columbia, United States, 20007 United States, Maryland Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States, 21287 United States, Massachusetts Massachusetts General Hospital Cancer Center Boston, Massachusetts, United States, 02114 Brigham and Women's Hospital Boston, Massachusetts, United States, 02115 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, Ohio Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States, 43210 United States, Pennsylvania University of Pittsburgh Cancer Institute (UPCI) Pittsburgh, Pennsylvania, United States, 15232 United States, Texas M D Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT01661868	Ovarian Cancer\|Peritoneal Canc... More >>er\|Fallopian Tube Cancer Less <<	PHASE2	WITHDRAWN	2025-08-12	Dana-Farber Cancer Institute, ... More >>Boston, Massachusetts, 02215, United States Less <<
NCT03233204	Advanced Malignant Solid Neopl... More >>asm\|Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma\|Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma\|Low Grade Glioma\|Malignant Glioma\|Recurrent Childhood Central Nervous System Neoplasm\|Recurrent Childhood Ependymoma\|Recurrent Childhood Malignant Germ Cell Tumor\|Recurrent Childhood Non-Hodgkin Lymphoma\|Recurrent Childhood Rhabdomyosarcoma\|Recurrent Childhood Soft Tissue Sarcoma\|Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor\|Recurrent Glioma\|Recurrent Hepatoblastoma\|Recurrent Langerhans Cell Histiocytosis\|Recurrent Malignant Solid Neoplasm\|Recurrent Medulloblastoma\|Recurrent Neuroblastoma\|Recurrent Osteosarcoma\|Refractory Childhood Malignant Germ Cell Tumor\|Refractory Ependymoma\|Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor\|Refractory Glioma\|Refractory Hepatoblastoma\|Refractory Langerhans Cell Histiocytosis\|Refractory Malignant Glioma\|Refractory Malignant Solid Neoplasm\|Refractory Medulloblastoma\|Refractory Neuroblastoma\|Refractory Non-Hodgkin Lymphoma\|Refractory Osteosarcoma\|Refractory Primary Central Nervous System Neoplasm\|Refractory Rhabdomyosarcoma\|Refractory Soft Tissue Sarcoma\|Rhabdoid Tumor\|Wilms Tumor Less <<	PHASE2	COMPLETED	2024-06-30	Children's Hospital of Alabama... More >>, Birmingham, Alabama, 35233, United States\|Providence Alaska Medical Center, Anchorage, Alaska, 99508, United States\|Banner Children's at Desert, Mesa, Arizona, 85202, United States\|Banner University Medical Center - Tucson, Tucson, Arizona, 85719, United States\|Arkansas Children's Hospital, Little Rock, Arkansas, 72202-3591, United States\|Kaiser Permanente Downey Medical Center, Downey, California, 90242, United States\|Loma Linda University Medical Center, Loma Linda, California, 92354, United States\|Miller Children's and Women's Hospital Long Beach, Long Beach, California, 90806, United States\|Children's Hospital Los Angeles, Los Angeles, California, 90027, United States\|Valley Children's Hospital, Madera, California, 93636, United States\|UCSF Benioff Children's Hospital Oakland, Oakland, California, 94609, United States\|Kaiser Permanente-Oakland, Oakland, California, 94611, United States\|UCSF Medical Center-Mission Bay, San Francisco, California, 94158, United States\|Children's Hospital Colorado, Aurora, Colorado, 80045, United States\|Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver, Colorado, 80218, United States\|Yale University, New Haven, Connecticut, 06520, United States\|Alfred I duPont Hospital for Children, Wilmington, Delaware, 19803, United States\|Children's National Medical Center, Washington, District of Columbia, 20010, United States\|University of Florida Health Science Center - Gainesville, Gainesville, Florida, 32610, United States\|Nemours Children's Clinic-Jacksonville, Jacksonville, Florida, 32207, United States\|University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida, 33136, United States\|Nicklaus Children's Hospital, Miami, Florida, 33155, United States\|AdventHealth Orlando, Orlando, Florida, 32803, United States\|Arnold Palmer Hospital for Children, Orlando, Florida, 32806, United States\|Nemours Children's Hospital, Orlando, Florida, 32827, United States\|Nemours Children's Clinic - Pensacola, Pensacola, Florida, 32504, United States\|Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa, Florida, 33607, United States\|Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, 30322, United States\|Saint Luke's Cancer Institute - Boise, Boise, Idaho, 83712, United States\|University of Illinois, Chicago, Illinois, 60612, United States\|University of Chicago Comprehensive Cancer Center, Chicago, Illinois, 60637, United States\|Saint Jude Midwest Affiliate, Peoria, Illinois, 61637, United States\|Southern Illinois University School of Medicine, Springfield, Illinois, 62702, United States\|Riley Hospital for Children, Indianapolis, Indiana, 46202, United States\|Blank Children's Hospital, Des Moines, Iowa, 50309, United States\|University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, 52242, United States\|Norton Children's Hospital, Louisville, Kentucky, 40202, United States\|Children's Hospital New Orleans, New Orleans, Louisiana, 70118, United States\|Ochsner Medical Center Jefferson, New Orleans, Louisiana, 70121, United States\|Eastern Maine Medical Center, Bangor, Maine, 04401, United States\|Sinai Hospital of Baltimore, Baltimore, Maryland, 21215, United States\|Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, 21287, United States\|C S Mott Children's Hospital, Ann Arbor, Michigan, 48109, United States\|Bronson Methodist Hospital, Kalamazoo, Michigan, 49007, United States\|Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis, Minnesota, 55404, United States\|University of Minnesota/Masonic Cancer Center, Minneapolis, Minnesota, 55455, United States\|Mayo Clinic in Rochester, Rochester, Minnesota, 55905, United States\|University of Mississippi Medical Center, Jackson, Mississippi, 39216, United States\|Children's Mercy Hospitals and Clinics, Kansas City, Missouri, 64108, United States\|Cardinal Glennon Children's Medical Center, Saint Louis, Missouri, 63104, United States\|Washington University School of Medicine, Saint Louis, Missouri, 63110, United States\|Mercy Hospital Saint Louis, Saint Louis, Missouri, 63141, United States\|Children's Hospital and Medical Center of Omaha, Omaha, Nebraska, 68114, United States\|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States\|University Medical Center of Southern Nevada, Las Vegas, Nevada, 89102, United States\|Alliance for Childhood Diseases/Cure 4 the Kids Foundation, Las Vegas, Nevada, 89135, United States\|Summerlin Hospital Medical Center, Las Vegas, Nevada, 89144, United States\|Hackensack University Medical Center, Hackensack, New Jersey, 07601, United States\|Morristown Medical Center, Morristown, New Jersey, 07960, United States\|Rutgers Cancer Institute of New Jersey-Robert Wood Johnson University Hospital, New Brunswick, New Jersey, 08903, United States\|Albany Medical Center, Albany, New York, 12208, United States\|Roswell Park Cancer Institute, Buffalo, New York, 14263, United States\|NYU Langone Hospital - Long Island, Mineola, New York, 11501, United States\|The Steven and Alexandra Cohen Children's Medical Center of New York, New Hyde Park, New York, 11040, United States\|NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, 10032, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States\|NYP/Weill Cornell Medical Center, New York, New York, 10065, United States\|University of Rochester, Rochester, New York, 14642, United States\|State University of New York Upstate Medical University, Syracuse, New York, 13210, United States\|New York Medical College, Valhalla, New York, 10595, United States\|Mission Hospital, Asheville, North Carolina, 28801, United States\|Carolinas Medical Center/Levine Cancer Institute, Charlotte, North Carolina, 28203, United States\|Novant Health Presbyterian Medical Center, Charlotte, North Carolina, 28204, United States\|Duke University Medical Center, Durham, North Carolina, 27710, United States\|Sanford Broadway Medical Center, Fargo, North Dakota, 58122, United States\|Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, 45229, United States\|Cleveland Clinic Foundation, Cleveland, Ohio, 44195, United States\|Nationwide Children's Hospital, Columbus, Ohio, 43205, United States\|Dayton Children's Hospital, Dayton, Ohio, 45404, United States\|ProMedica Toledo Hospital/Russell J Ebeid Children's Hospital, Toledo, Ohio, 43606, United States\|University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, 73104, United States\|Legacy Emanuel Children's Hospital, Portland, Oregon, 97227, United States\|Oregon Health and Science University, Portland, Oregon, 97239, United States\|Geisinger Medical Center, Danville, Pennsylvania, 17822, United States\|Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, 19104, United States\|Children's Hospital of Pittsburgh of UPMC, Pittsburgh, Pennsylvania, 15224, United States\|Prisma Health Richland Hospital, Columbia, South Carolina, 29203, United States\|BI-LO Charities Children's Cancer Center, Greenville, South Carolina, 29605, United States\|Sanford USD Medical Center - Sioux Falls, Sioux Falls, South Dakota, 57117-5134, United States\|East Tennessee Childrens Hospital, Knoxville, Tennessee, 37916, United States\|Saint Jude Children's Research Hospital, Memphis, Tennessee, 38105, United States\|Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, 37232, United States\|Dell Children's Medical Center of Central Texas, Austin, Texas, 78723, United States\|Medical City Dallas Hospital, Dallas, Texas, 75230, United States\|UT Southwestern/Simmons Cancer Center-Dallas, Dallas, Texas, 75390, United States\|Cook Children's Medical Center, Fort Worth, Texas, 76104, United States\|Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston, Texas, 77030, United States\|M D Anderson Cancer Center, Houston, Texas, 77030, United States\|Children's Hospital of San Antonio, San Antonio, Texas, 78207, United States\|Methodist Children's Hospital of South Texas, San Antonio, Texas, 78229, United States\|Scott and White Memorial Hospital, Temple, Texas, 76508, United States\|Primary Children's Hospital, Salt Lake City, Utah, 84113, United States\|University of Vermont and State Agricultural College, Burlington, Vermont, 05405, United States\|Children's Hospital of The King's Daughters, Norfolk, Virginia, 23507, United States\|Virginia Commonwealth University/Massey Cancer Center, Richmond, Virginia, 23298, United States\|Seattle Children's Hospital, Seattle, Washington, 98105, United States\|Providence Sacred Heart Medical Center and Children's Hospital, Spokane, Washington, 99204, United States\|Madigan Army Medical Center, Tacoma, Washington, 98431, United States\|West Virginia University Healthcare, Morgantown, West Virginia, 26506, United States\|University of Wisconsin Carbone Cancer Center - University Hospital, Madison, Wisconsin, 53792, United States\|Children's Hospital of Wisconsin, Milwaukee, Wisconsin, 53226, United States\|San Jorge Children's Hospital, San Juan, 00912, Puerto Rico\|University Pediatric Hospital, San Juan, 00926, Puerto Rico Less <<
NCT01844986	Newly Diagnosed ... More >> Advanced Ovarian Cancer FIGO Stage III-IV BRCA Mutation Complete Response Partial Response First Line Platinum Chemotherapy Less <<	Phase 3	Active, not recruiting	June 6, 2023	-
NCT01858168	Ewing Sarcoma	Phase 1	Recruiting	July 2020	United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Barbara Anderson, RN 617-724-4000 banderson@partners.org Contact: Sienna Durbin, BS 617-724-4000 Principal Investigator: Edwin Choy, MD, PhD Boston Children's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Steven Dubois, MD 617-632-5460 Steven_Dubois@dfci.harvard.edu Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02215 Contact: Melissa Hohos, RN 617-582-7162 mhohos@partners.org Contact: Mark Morley, RN 617-632-3989 mmorley@partners.org Principal Investigator: George Demetri, MD Dana-Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Melissa Hohos, RN 617-582-7162 mhohos@partners.org Contact: Mark Morley, RN 617-632-3989 mmorley@partners.org Principal Investigator: George Demetri, MD United States, Tennessee St. Jude's Children's Research Hospital Recruiting Memphis, Tennessee, United States, 38105 Contact: Sara Federico, MD 866-278-5833 sara.federico@stjude.org Less <<
NCT03428607	SCLC	Phase 2	Not yet recruiting	June 2020	-
NCT03263650	Prostate Cancer Aggressiveness... More >> Prostate Carcinoma Less <<	Phase 2	Recruiting	October 2021	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact: Ana M. Aparicio, MD 713-792-2830 Less <<
NCT02489006	Ovarian Cancer ... More >> Fallopian Tube Cancer Neoadjuvant Treatment Debulking Surgical Procedures Less <<	Phase 2	Recruiting	June 2019	Canada, Alberta ... More >> Tom Baker Cancer Centre Recruiting Calgary, Alberta, Canada, T2N 4N2 Contact: Prafull Ghatage, M.D. 403-521-3721 Principal Investigator: Prafull Ghatage, M.D. Canada, Ontario Juravinski Cancer Centre Not yet recruiting Hamilton, Ontario, Canada, L8V 5C2 Contact: Holger (Hal) Hirte, M.D. (905) 387-9495 Principal Investigator: Holger (Hal) Hirte, M.D. London Regional Cancer Centre Not yet recruiting London, Ontario, Canada, N6A 4L6 Contact: Stephen Welch, M.D. 416-685-8640 Ottawa Regional Cancer Centre Not yet recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: Johanne Weberpals, M.D. 519-737-8899 ext. 76462 Principal Investigator: Johanne Weberpals, M.D. Princess Margaret Cancer Centre Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Amit Oza, M.D 416-946-2818 Principal Investigator: Amit Oza, M.D Canada, Quebec Hôpital Notre-Dame Not yet recruiting Montréal, Quebec, Canada, H2L 4M1 Contact: Diane Provencher, M.D. 514-890-8000 ext 27244 Principal Investigator: Diane Provencher, M.D. Less <<
NCT01851265	Solid Tumours	Phase 1	Completed	-	Belgium ... More >> Research Site Edegem, Belgium, 2650 Research Site Leuven, Belgium, 3000 Research Site Wilrijk, Belgium, 2610 Netherlands Research Site Amsterdam, Netherlands, 1081 HV Research Site Maastricht, Netherlands, 6202 AZ United Kingdom Research Site Glasgow, United Kingdom, G12 0YN Research Site Manchester, United Kingdom, M20 4BX Less <<
NCT03732820	Metastatic Castration-resistan... More >>t Prostate Cancer Less <<	Phase 3	Recruiting	August 17, 2022	-
NCT02184195	Germline BRCA1/2 Mutations and... More >> Metastatic Adenocarcinoma of the Pancreas Less <<	Phase 3	Recruiting	July 31, 2019	-
NCT02324998	Prostate Cancer	Phase 1	Recruiting	July 2018	United Kingdom ... More >> Addenbrooke's Hospital, Cambridge University Hospitals Foundation Trust, Recruiting Cambridge, Cambridgeshire, United Kingdom, CB2 0QQ Contact: Ruth Tysoe, BSc. 01223 348089 ruth.tysoe@addenbrookes.nhs.uk Contact: Simon Pacey, MRCP, Ph.D 01223 769 480 scp46@medschl.cam.ac.uk Less <<
NCT01921140	Solid Tumours	Phase 1	Active, not recruiting	December 28, 2018	Belgium ... More >> Research Site Brussels, Belgium, 1090 Research Site Leuven, Belgium, 3000 Research Site Liege, Belgium, 4000 Denmark Research Site Herlev, Denmark, 2730 Research Site København Ø, Denmark, 2100 Netherlands Research Site Maastricht, Netherlands, 6202 AZ Research Site Nijmegen, Netherlands, 6525 GA Research Site Utrecht, Netherlands, 3584 CX United Kingdom Research Site London, United Kingdom, SE1 9RT Research Site Newcastle-Upon-Tyne, United Kingdom, NE7 7DN Research Site Surrey, United Kingdom, SM1 2DL Less <<
NCT03544125	Anatomic Stage IV Breast Cance... More >>r AJCC v8 Estrogen Receptor Negative HER2/Neu Negative Progesterone Receptor Negative Prognostic Stage IV Breast Cancer AJCC v8 Triple-Negative Breast Carcinoma Less <<	Phase 1	Recruiting	December 16, 2020	United States, Oregon ... More >> OHSU Knight Cancer Institute Recruiting Portland, Oregon, United States, 97239 Contact: Zahi Mitri, MD 503-494-9160 mitri@ohsu.edu Principal Investigator: Zahi Mitri, MD Less <<
NCT03009682	Small Cell Lung Cancer	PHASE2	COMPLETED	2025-01-21	Samsung Medical Center, Seoul,... More >> 135-710, Korea, Republic of Less <<
NCT02208375	Breast Cancer ... More >> Malignant Female Reproductive System Neoplasm Less <<	Phase 1 Phase 2	Active, not recruiting	November 2021	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03375307	Abnormal DNA Repair ... More >> ATM Gene Mutation ATR Gene Mutation BAP1 Gene Mutation BARD1 Gene Mutation BLM Gene Mutation BRCA1 Gene Mutation BRCA2 Gene Mutation BRIP1 Gene Mutation CHEK1 Gene Mutation CHEK2 Gene Mutation FANCC Gene Mutation FANCD2 Gene Mutation FANCE Gene Mutation FANCF Gene Mutation MEN1 Gene Mutation Metastatic Urothelial Carcinoma MLH1 Gene Mutation MSH2 Gene Mutation MSH6 Gene Mutation MUTYH Gene Mutation NPM1 Gene Mutation PALB2 Gene Mutation PMS2 Gene Mutation POLD1 Gene Mutation POLE Gene Mutation PRKDC Gene Mutation RAD50 Gene Mutation RAD51 Gene Mutation SMARCB1 Gene Mutation Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 Stage IV Bladder Urothelial Carcinoma AJCC v7 STK11 Gene Mutation Urothelial Carcinoma Less <<	Phase 2	Not yet recruiting	December 31, 2022	-
NCT02446704	Small Cell Lung Cancer	Phase 1 Phase 2	Recruiting	August 2022	United States, Massachusetts ... More >> Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Anna Farago, MD, PhD 617-724-4000 afarago@mgh.harvard.edu Principal Investigator: Anna Farago, MD, PhD Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02115 Contact: David Barbie, MD 617-632-6049 dbarbie@partners.org Principal Investigator: David Barbie, MD Beth Israel Deaconess Medical Center Active, not recruiting Boston, Massachusetts, United States, 02215 Less <<
NCT02506816	Endometrial Carcinoma		COMPLETED	2025-03-19	MedSIR investigative site, Bar... More >>celona, 08035, Spain\|MedSIR investigative site, Barcelona, 08036, Spain\|MedSIR investigative site, Cordoba, 14004, Spain\|MedSIR investigative site, Coru?a, 15006, Spain\|MedSIR investigative site, Granollers, 08400, Spain\|MedSIR, Madrid, 28034, Spain\|MedSIR investigative site, Madrid, 28040, Spain\|MedSIR investigative site, Santiago De Compostela, 15706, Spain\|MedSIR investigative site, Valencia, 46009, Spain\|MedSIR investigative site, Vigo, 36312, Spain Less <<
NCT03462342	High Grade Serous Carcinoma	Phase 2	Recruiting	December 31, 2021	United States, Pennsylvania ... More >> Gynecology Oncology Division Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: Reena Rai, MS 215-615-6740 reena.rai@uphs.upenn.edu Less <<
NCT01583543	Ewing's Sarcoma	PHASE2	COMPLETED	2025-11-14	Massachusetts General Hospital... More >>, Boston, Massachusetts, 02115, United States\|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT03594396	Breast Neoplasms	Phase 1 Phase 2	Recruiting	April 30, 2020	Korea, Republic of ... More >> Seoul National University Hospital Recruiting Seoul, Korea, Republic of Contact: Seock-Ah Im 82-2-2072-0850 moisa@snu.ac.kr Less <<
NCT03598257	Inflammatory Breast Carcinoma	Phase 2	Recruiting	July 31, 2023	United States, Illinois ... More >> Carle Cancer Center Recruiting Urbana, Illinois, United States, 61801 Contact: Site Public Contact 800-446-5532 Research@carle.com Principal Investigator: Kalika P. Sarma United States, Iowa Iowa Methodist Medical Center Recruiting Des Moines, Iowa, United States, 50309 Contact: Site Public Contact 515-241-6727 Principal Investigator: Robert J. Behrens United States, Montana Bozeman Deaconess Hospital Recruiting Bozeman, Montana, United States, 59715 Contact: Site Public Contact 406-969-6060 mccinfo@mtcancer.org Principal Investigator: Benjamin T. Marchello United States, Nebraska Nebraska Methodist Hospital Recruiting Omaha, Nebraska, United States, 68114 Contact: Site Public Contact 402-354-5144 Principal Investigator: Kirsten M. Leu United States, Oklahoma University of Oklahoma Health Sciences Center Recruiting Oklahoma City, Oklahoma, United States, 73104 Contact: Site Public Contact 405-271-8777 ou-clinical-trials@ouhsc.edu Principal Investigator: Sobia Nabeel United States, Oregon Providence Saint Vincent Medical Center Recruiting Portland, Oregon, United States, 97225 Contact: Site Public Contact 503-215-2614 CanRsrchStudies@providence.org Principal Investigator: Gary E. Goodman Less <<
NCT02889900	Recurrent Platinum Resistant O... More >>varian Cancer Less <<	Phase 2	Recruiting	December 20, 2019	-
NCT01583543	Ewing's Sarcoma	PHASE2	COMPLETED	2025-11-14	Massachusetts General Hospital... More >>, Boston, Massachusetts, 02115, United States\|Brigham and Women's Hospital, Boston, Massachusetts, 02215, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States Less <<
NCT03772561	Solid Tumor, Adult	Phase 1	Recruiting	December 31, 2023	Singapore ... More >> National University Hospital Recruiting Singapore, Singapore, 119074 Contact: David SP Tan 65 6779 5555 david_sp_tan@nuhs.edu.sg Less <<
NCT03570476	ATM Biallelic Inactivation ... More >> ATM Gene Mutation ATM Monoallelic Inactivation BRCA1 Biallelic Inactivation BRCA1 Gene Mutation BRCA2 Biallelic Inactivation BRCA2 Gene Mutation FANCA Biallelic Inactivation Homologous Recombination Deficiency PALB2 Biallelic Inactivation PALB2 Gene Mutation Prostate Adenocarcinoma Without Evidence of Neuroendocrine Differentiation Stage I Prostate Cancer AJCC v8 Stage II Prostate Cancer AJCC v8 Stage IIA Prostate Cancer AJCC v8 Stage IIB Prostate Cancer AJCC v8 Stage IIC Prostate Cancer AJCC v8 Less <<	Phase 2	Recruiting	January 1, 2022	United States, Washington ... More >> Fred Hutch/University of Washington Cancer Consortium Recruiting Seattle, Washington, United States, 98109 Contact: Robert B. Montgomery 206-598-0860 rbmontgo@uw.edu Principal Investigator: Robert B. Montgomery Less <<
NCT03057145	Solid Tumor	Phase 1	Recruiting	February 25, 2023	United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Khanh Do, MD 617-632-6992 Principal Investigator: Khanh Do, MD Less <<
NCT02398058	Soft Tissue Sarcoma ... More >> Bone Tumor Less <<	Phase 1	Active, not recruiting	January 2019	Italy ... More >> Fondazione del Piemonte per l'Oncologia IRCC Candiolo Candiolo, Torino, Italy, 10060 Istituti Ortopedici Rizzoli - Unit of Chemotherapy of Muscoloskeletal Tumors Bologna, Italy, 40136 Istituto Nazionale Tumori - Unit of Medical Oncology Milano, Italy, 20133 Less <<
NCT01758731	Squamous Cell Carcinoma of the... More >> Head and Neck Less <<	Phase 1	Completed	-	United States, Colorado ... More >> University of Colorado Denver Denver, Colorado, United States, 80045 Less <<
NCT02681562	Breast Cancer ... More >> Triple Negative Breast Cancer Less <<	Phase 2	Unknown	-	-
NCT01929603	Solid Tumours	Phase 1	Completed	-	Belgium ... More >> Research Site Edegem, Belgium Research Site Gent, Belgium Research Site Wilrijk, Belgium Netherlands Research Site Amsterdam, Netherlands Research Site Maastricht, Netherlands Less <<
NCT02032823	Breast Cancer	Phase 3	Recruiting	November 27, 2028	-
NCT01623349	Ovarian Cancer ... More >> Breast Cancer Less <<	Phase 1	Active, not recruiting	December 2019	United States, Massachusetts ... More >> Massachusetts General Hospital Boston, Massachusetts, United States, 02114 Beth Israel Deaconess Medical Center Boston, Massachusetts, United States, 02215 Dana-Farber Cancer Institute Boston, Massachusetts, United States, 02215 United States, New York Memorial Sloan-Kettering Cancer Center New York, New York, United States, 10065 United States, Texas MD Anderson Cancer Center Houston, Texas, United States, 77230 Less <<
NCT02229656	Laryngeal Cancer Stage II ... More >> Laryngeal Cancer Stage III Carcinoma, Squamous Cell Head and Neck Neoplasms Less <<	Phase 1	Recruiting	August 2020	Netherlands ... More >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066 CX Contact: Marcel Verheij, MD, PhD +31 20 512 2153 m.verheij@nki.nl Contact: Rosemarie de Haan, MD +31 20 512 9085 ro.d.haan@nki.nl Principal Investigator: Marcel Verheij, MD, PhD Sub-Investigator: Margot Tesselaar, MD, PhD Sub-Investigator: Abrahim Al-Mamgani, MD, PhD Less <<
NCT02511795	Refractory Solid Tumours ... More >> Relapsed Small Cell Lung Cancer (SCLC) Less <<	Phase 1	Recruiting	September 27, 2019	United States, Colorado ... More >> Research Site Recruiting Denver, Colorado, United States, 80218 United States, Florida Research Site Recruiting Sarasota, Florida, United States, 34232 United States, New York Research Site Recruiting New York, New York, United States, 10033 United States, Tennessee Research Site Recruiting Nashville, Tennessee, United States, 37203 United States, Texas Research Site Recruiting Houston, Texas, United States, 77030 Canada, Ontario Research Site Active, not recruiting Toronto, Ontario, Canada, M5G 2M9 Less <<
NCT02787642	Soft-tissue Sarcoma	Phase 1	Recruiting	December 2020	France ... More >> Institut Bergonié Recruiting Bordeaux, France, 33076 Contact: Paul SARGOS, MD s.sargos@bordeaux.unicancer.fr Centre Oscar Lambret Not yet recruiting Lille, France, 59020 Contact: Nicolas PENEL, MD-PhD n-penel@o-lambret.fr Centre Léon Bérard Recruiting Lyon, France, 69373 Contact: Marie-Pierre SUNYACH, MD marie-pierre.sunyach@lyon.unicancer.fr Institut du Cancer de Montpellier Not yet recruiting Montpellier, France, 34298 Contact: Carmen LLACER-MOSCARDO, MD carmen.llacer@icm.unicancer.fr Institut Claudius Regaud - IUCT Recruiting Toulouse, France, 31052 Contact: Christine CHEVREAU, MD chevreau.christine@iuct-oncopole.fr Institut Gustave Roussy Not yet recruiting Villejuif, France, 94800 Contact: Axel LE CESNE, MD axel.lecesne@gustaveroussy.fr Less <<
NCT03161132	Advanced Ovarian Cancer	Phase 2	Recruiting	December 2020	Spain ... More >> Corporación Sanitaria Parc Taulí Recruiting Sabadell, Barcelona, Spain Contact: Yolanda García García, M.D. +34 93 724 00 84 ygarcia@tauli.cat Principal Investigator: Yolanda García García, M.D. Hospital Universitario de Gran Canaria Doctor Negrín Recruiting Palmas de Gran Canaria, Gran Canaria, Spain Contact: Uriel Bohn Sarmiento, M.D. +34 928 450 400 ubosar@gmail.com Principal Investigator: Uriel Bohn Sarmiento, M.D. Hospital Son Llatzer Recruiting Palma De Mallorca, Mallorca, Spain Contact: María Iglesias González, M.D. +34 871 202 000 ext 2103 miglegon@hsll.es Principal Investigator: María Iglesias González, M.D. Hospital Universitario Ramón y Cajal Recruiting Madrid, Spain, 28034 Contact: Alfonso Cortés, M.D. +34 91 336 80 00 acsalgado86@gmail.com Principal Investigator: Alfonso Cortés, M.D. Hospital Universitario 12 de Octubre Recruiting Madrid, Spain Contact: Luis Manso Sánchez, M.D. +34 913908003 luis_manso@hotmail.com Principal Investigator: Luis Manso Sánchez, M.D. Hospital Universitario Virgen del Rocío Recruiting Sevilla, Spain Contact: Elisa Calvo García, M.D. +34 955 013 068 elisa.calvo.garcia@gmail.com Principal Investigator: Elisa Calvo García, M.D. Hospital Universitario y Politécnico La Fe Recruiting Valencia, Spain, 46009 Contact: Ana Santaballana, M.D. +34 961 244 188 santaballa_ana@gva.es Principal Investigator: Ana Santaballa, M.D. Hospital Clínico Universitario de Valencia Recruiting Valencia, Spain Contact: José A Pérez Fidalgo, M.D. +34 963862625 japfidalgo@msn.com Principal Investigator: José A Pérez Fidalgo, M.D. Less <<
NCT02227082	Locally Advanced Malignant Neo... More >>plasm Inflammatory Breast Carcinoma Triple-Negative Invasive Breast Carcinoma Less <<	Phase 1	Recruiting	August 2020	Netherlands ... More >> The Netherlands Cancer Institute Recruiting Amsterdam, Netherlands, 1066 CX Contact: Gabe Sonke, MD, PhD + 31 20 512 29251 g.sonke@nki.nl Contact: Rosemarie de Haan, MD + 31 20 512 9085 ro.d.haan@nki.nl Principal Investigator: Gabe Sonke, MD, PhD Less <<
NCT03330847	Metastatic Triple Negative Bre... More >>ast Cancer Less <<	Phase 2	Recruiting	January 20, 2021	-
NCT03641755	Breast Cancer	Phase 1 Phase 2	Recruiting	June 22, 2025	United States, Massachusetts ... More >> Dana Farber Cancer Institute Recruiting Boston, Massachusetts, United States, 02215 Contact: Sara M. Tolaney, MD MPH 617-632-2335 Sara_Tolaney@dfci.harvard.edu Principal Investigator: Sara M. Tolaney, MD MPH Broad Institute of MIT Active, not recruiting Cambridge, Massachusetts, United States, 02142 Less <<
NCT03106987	Epithelial Ovarian Cancer	Phase 3	Recruiting	May 7, 2021	-
NCT01682772	Adenocarcinoma of the Prostate	PHASE2	UNKNOWN	2025-02-20	Royal Marsden NHS Foundation T... More >>rust, Sutton, Surrey, SM2 5PT, United Kingdom\|University College Hospital London, London, NW1 2BU, United Kingdom Less <<
NCT03432897	Prostate Cancer ... More >> Adenocarcinoma of the Prostate Less <<	Phase 2	Recruiting	September 2021	United States, Rhode Island ... More >> Lifespan Cancer Institute: The Miriam and Rhode Island Hospitals Recruiting Providence, Rhode Island, United States, 02903 Contact: Kayla Rosati, EdM 401-863-3000 kayla_rosati@brown.edu Principal Investigator: Anothony Mega, MD Less <<
NCT03745950	Endometrial Carcinoma	Phase 2	Not yet recruiting	December 2024	France ... More >> ICO Paul Papin Not yet recruiting Angers, France Contact: Sophie ABADIE-LACOURTOISIE Institut Sainte Catherine Not yet recruiting Avignon, France Contact: Julien GRENIER CHRU Jean Minjoz Not yet recruiting Besançon, France Contact: Elsa KALBACHER Institut Bergonié Not yet recruiting Bordeaux, France Contact: Anne FLOQUET Centre François Baclesse Not yet recruiting Caen, France Contact: Pierre-Emmanuel BRACHET Centre Jean Perrin Not yet recruiting Clermont-Ferrand, France Contact: Marie-Ange MOURET-REYNIER Centre Hospitalier Intercommunal de Créteil Not yet recruiting Créteil, France Contact: Isabelle COJEAN-ZELEK Centre Georges François Leclerc Not yet recruiting Dijon, France Contact: Leila BENGRINE Institut Daniel Hollard - GHM de Grenoble Not yet recruiting Grenoble, France Contact: Claire GARNIER TIXIDRE Clinique Victor Hugo Not yet recruiting Le Mans, France Contact: Hugues BOURGEOIS Centre Oscar Lambret Not yet recruiting Lille, France Contact: Annick CHEVALIER Centre Léon Bérard Not yet recruiting Lyon, France Contact: Pierre HEUDEL Hôpital Saint-Joseph Not yet recruiting Marseille, France Contact: Cyril FOA Centre Hospitalier de Mont-De-Marsan Not yet recruiting Mont-de-Marsan, France Contact: Jérôme DAUBA ICM Val d'Aurelle Not yet recruiting Montpellier, France Contact: Michel FABBRO Centre Azuréen de Cancérologie Not yet recruiting Mougins, France Contact: Rémy LARGILLIER Centre d'Oncologie de Gentilly Not yet recruiting Nancy, France Contact: Célia ROEMER-BECUWE Hôpital Privé du Confluent SAS Not yet recruiting Nantes, France Contact: Alain LORTHOLARY Centre Antoine Lacassagne Not yet recruiting Nice, France Contact: Philippe FOLLANA CHU de Nîmes Not yet recruiting Nîmes, France Contact: Miruna TIMAR-DAVID CHR d'Orléans Not yet recruiting Orléans, France Contact: Corina CORNILA Groupe Hospitalier Diaconesses Croix Saint-Simon Not yet recruiting Paris, France Contact: Frédéric SELLE HEGP Not yet recruiting Paris, France Contact: Emilie BOISSIER Hôpital Cochin Not yet recruiting Paris, France Contact: Jérôme ALEXANDRE Institut Curie - Hopital Claudius Régaud Not yet recruiting Paris, France Contact: Manuel RODRIGUES Centre Hospitalier Lyon Sud Not yet recruiting Pierre Benite, France Contact: Benoît YOU Centre CARIO - HPCA Not yet recruiting Plérin, France Contact: Anne-Claire HARDY-BESSARD CHU de Poitiers Not yet recruiting Poitiers, France Contact: Nadia RABAN Polyclinique Francheville Not yet recruiting Périgueux, France Contact: Charles-Briac LEVACHE Centre Henri Becquerel Not yet recruiting Rouen, France Contact: Cécile GUILLEMET ICO Centre René Gauducheau Not yet recruiting Saint-Herblain, France Contact: Jean-Sébastien FRENEL Institut de Cancérologie Lucien Neuwirth Not yet recruiting Saint-Priest-en-Jarez, France Contact: Olivier COLLARD Hôpitaux Universitaires de Strasbourg Not yet recruiting Strasbourg, France Contact: Laure DE COCK Institut Claudius Régaud Not yet recruiting Toulouse, France Contact: Laurence GLADIEFF Institut de Cancérologie de Lorraine Not yet recruiting Vandoeuvre les nancy, France Contact: Yolanda FERNANDEZ Gustave Roussy Not yet recruiting Villejuif, France Contact: Alexandra LEARY Less <<
NCT03742245	Breast Cancer Metastatic ... More >> Breast Cancer Less <<	Phase 1	Not yet recruiting	September 1, 2022	United States, Texas ... More >> Houston Methodist Cancer Center Houston, Texas, United States, 77030 Less <<
NCT03167619	Triple Negative Breast Cancer	Phase 2	Recruiting	December 2020	United States, North Carolina ... More >> Duke University Recruiting Durham, North Carolina, United States, 27705 Contact: Sarah Sammons, MD Less <<
NCT03162627	Malignant Neoplasm of Breast ... More >> Malignant Neoplasms of Digestive Organs Malignant Neoplasms of Female Genital Organs Malignant Neoplasms of Male Genital Organs Malignant Neoplasms of Thyroid and Other Endocrine Glands Less <<	Phase 1	Recruiting	August 2026	United States, Texas ... More >> University of Texas MD Anderson Cancer Center Recruiting Houston, Texas, United States, 77030 Contact swestin@mdanderson.org Less <<
NCT03470805	Ovarian Cancer	PHASE2	COMPLETED	2022-07-27	ICO Badalona, Badalona, Spain\|... More >>H Reina Sofía Cordoba, Cordoba, 14004, Spain\|Hospital de Guadalajara, Guadalajara, Spain\|Complejo Hospitalario de Jaen, Jaén, Spain\|Hospital de Jerez de la Frontera, Jerez De La Frontera, Spain\|Hospital Lucus Augusti, Lugo, Spain\|Hospital Universitario La Paz, Madrid, 28046, Spain\|Fundación Jimenez Diaz, Madrid, Spain\|Hospital Ramon y Cajal, Madrid, Spain\|Hospital Universitario 12 de Octubre, Madrid, Spain\|Hospital Universitario Puerta de Hierro, Madrid, Spain\|Hospital Clinico Universitario Virgen Arrixaca, Murcia, Spain\|Hospital Universitario de Valdecilla, Santander, 39008, Spain\|Hospital Universitario Virgen del Rocío, Sevilla, Spain\|Hospital Virgen Macarena, Sevilla, Spain\|Instituto Valenciano de Oncología, Valencia, 46009, Spain Less <<
NCT03742895	Advanced Solid Neoplasms	PHASE2	ACTIVE_NOT_RECRUITING	2026-06-30	The University of Arizona Canc... More >>er Center - North Campus ( Site 0011), Tucson, Arizona, 85719, United States\|St Joseph Heritage Healthcare-Oncology ( Site 0056), Fullerton, California, 92835, United States\|Cedars Sinai Medical Center ( Site 0002), Los Angeles, California, 90048, United States\|UCSF Helen Diller Family Comprehensive Cancer Center ( Site 0007), San Francisco, California, 94158, United States\|Rocky Mountain Regional Veterans Affairs Medical Center ( Site 0092), Aurora, Colorado, 80045, United States\|Winship Cancer Institute of Emory University ( Site 0025), Atlanta, Georgia, 30322-1013, United States\|Augusta University ( Site 0028), Augusta, Georgia, 30912, United States\|Markey Cancer Center ( Site 0018), Lexington, Kentucky, 40536, United States\|University of Maryland ( Site 0050), Baltimore, Maryland, 21201, United States\|Weinberg Cancer Institute at Franklin Square ( Site 0054), Baltimore, Maryland, 21237, United States\|University of Massachusetts ( Site 0017), Worcester, Massachusetts, 01655, United States\|Henry Ford Health System ( Site 0060), Detroit, Michigan, 48202, United States\|Cancer Partners of Nebraska ( Site 0051), Lincoln, Nebraska, 68510, United States\|Memorial Sloan Kettering Cancer Center- Monmouth ( Site 0116), Middletown, New Jersey, 07748, United States\|Memorial Sloan-Kettering Cancer Center at West Harrison ( Site 0126), Harrison, New York, 10604, United States\|VA New York Harbor Healthcare System Manhattan ( Site 0094), New York, New York, 10010, United States\|Laura and Isaac Perlmutter Cancer Center at NYU Langone Health ( Site 0057), New York, New York, 10016, United States\|Memorial Sloan Kettering Cancer Center ( Site 0026), New York, New York, 10065, United States\|Southwestern Regional Medical Center, Inc. ( Site 0079), Tulsa, Oklahoma, 74133, United States\|Eastern Regional Medical Center, Inc. ( Site 0077), Philadelphia, Pennsylvania, 19124, United States\|Sanford Hematology Oncology-Sioux Falls SD ( Site 0012), Sioux Falls, South Dakota, 57104, United States\|Intermountain Healthcare ( Site 0043), Saint George, Utah, 84790, United States\|Virginia Mason Medical Center ( Site 0052), Seattle, Washington, 98101, United States\|Veterans Affairs Puget Sound Health Care System [Seattle, WA] ( Site 0093), Seattle, Washington, 98108, United States\|Centro de Oncologia e Investigacion Buenos Aires COIBA ( Site 2703), Berazategui, Buenos Aires, B1884BBF, Argentina\|Hospital Britanico de Buenos Aires ( Site 2704), Ciudad de Buenos Aires, Caba, C1280AEB, Argentina\|Instituto de Investigaciones Metabolicas ( Site 2700), Buenos Aires, C1012AAR, Argentina\|Hospital Aleman ( Site 2702), Buenos Aires, C1118AAT, Argentina\|Kinghorn Cancer Centre ( Site 2200), Darlinghurst, New South Wales, 2010, Australia\|MNCCI Port Macquarie Base Hospital ( Site 2201), Port Macquarie, New South Wales, 2444, Australia\|Linear Clinical Research Ltd ( Site 2202), Nedlands, Western Australia, 6009, Australia\|Sunnybrook Research Institute ( Site 0210), Toronto, Ontario, M4N 3M5, Canada\|Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0203), Montreal, Quebec, H1T 2M4, Canada\|Jewish General Hospital ( Site 0209), Montreal, Quebec, H3T 1E2, Canada\|Centre intégré de cancérologie du CHU de Québec Université Laval, H?pital de l'Enfant-Jésus ( Site 0, Quebec, G1J 1Z4, Canada\|Fundacion Centro de Investigacion Clinica CIC ( Site 2812), Medellin, Antioquia, 050021, Colombia\|Rodrigo Botero SAS ( Site 2801), Medellin, Antioquia, 050030, Colombia\|Biomelab S A S ( Site 2800), Barranquilla, Atlantico, 080001, Colombia\|Sociedad de Oncología Y Hematología del Cesar S.A.S. ( Site 2808), Valledupar, Cesar, 200001, Colombia\|Oncomedica S.A. ( Site 2806), Monteria, Cordoba, 230002, Colombia\|Administradora Country SA - Clinica del Country ( Site 2802), Bogota, Distrito Capital De Bogota, 110221, Colombia\|Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 2807), Bogota, Distrito Capital De Bogota, 110311, Colombia\|Instituto Nacional de Cancerologia E.S.E ( Site 2809), Bogota, Distrito Capital De Bogota, 111511, Colombia\|C. Medico Imbanaco Cali S.A. ( Site 2810), Cali, Valle Del Cauca, 760042, Colombia\|Rigshospitalet ( Site 0402), Copenhagen, Hovedstaden, 2100, Denmark\|Herlev og Gentofte Hospital. ( Site 0401), Herlev, Hovedstaden, 2730, Denmark\|Odense Universitetshospital ( Site 0400), Odense, Syddanmark, 5000, Denmark\|CHU Poitiers ( Site 0612), Poitiers, Ain, 86021, France\|Centre Antoine Lacassagne ( Site 0610), Nice, Alpes-Maritimes, 06189, France\|Institut de Cancerologie Strasbourg Europe ( Site 0613), Strasbourg, Alsace, 67033, France\|Centre Georges Francois Leclerc ( Site 0608), Dijon, Bourgogne, 21000, France\|Institut Bergonie ( Site 0603), Bordeaux, Gironde, 33076, France\|Institut Gustave Roussy ( Site 0601), Villejuif, Val-de-Marne, 94805, France\|Centro Regional de Sub Especialidades Medicas SA ( Site 3003), Guatemala, Quetzaltenango, 09001, Guatemala\|Centro de Investigaciones Clinicas de Latinoamerica S.A. - CELAN ( Site 3004), Guatemala, 01010, Guatemala\|Integra Cancer Institute ( Site 3006), Guatemala, 01010, Guatemala\|Grupo Angeles SA ( Site 3001), Guatemala, 01015, Guatemala\|Mater Misericordiae University Hospital ( Site 1654), Dublin, Carlow, D07 WKW8, Ireland\|Bon Secours Hospital ( Site 1656), Cork, T12 DV56, Ireland\|St. Vincent's University Hospital ( Site 1653), Dublin, 00004, Ireland\|Tallaght University Hospital ( Site 1652), Dublin, D24 NROA, Ireland\|Soroka Medical Center ( Site 0800), Beer-Sheva, 8457108, Israel\|Rambam Health Care Campus-Oncology Division ( Site 0801), Haifa, 3109601, Israel\|Hadassah Ein Kerem Medical Center ( Site 0802), Jerusalem, 9112001, Israel\|Chaim Sheba Medical Center ( Site 0803), Ramat Gan, 5262000, Israel\|Sourasky Medical Center ( Site 0804), Tel Aviv, 6423906, Israel\|Istituto Nazionale Tumori Fondazione Pascale ( Site 0700), Napoli, Campania, 80131, Italy\|Istituto Clinico Humanitas Research Hospital ( Site 0703), Rozzano, Lombardia, 20089, Italy\|Policlinico Le Scotte di Siena ( Site 0704), Siena, Toscana, 53100, Italy\|Aichi Cancer Center Hospital ( Site 2602), Nagoya, Aichi, 464-8681, Japan\|National Cancer Center Hospital East ( Site 2600), Kashiwa, Chiba, 2778577, Japan\|Kyoto University Hospital ( Site 2603), Kyoto-shi, Kyoto, 606-8507, Japan\|Osaka University Hospital ( Site 2604), Suita, Osaka, 565-0871, Japan\|National Cancer Center Hospital ( Site 2601), Tokyo, 104-0045, Japan\|The Cancer Institute Hospital of JFCR ( Site 2605), Tokyo, 135-8550, Japan\|Seoul National University Bundang Hospital ( Site 2402), Seongnam-si, Kyonggi-do, 13620, Korea, Republic of\|Seoul National University Hospital ( Site 2401), Seoul, 03080, Korea, Republic of\|Severance Hospital Yonsei University Health System ( Site 2400), Seoul, 03722, Korea, Republic of\|Actualidad Basada en la Investigacion del Cancer ( Site 2903), Guadalajara, Jalisco, 44680, Mexico\|Unidad Biomedica Avanzada Monterrey S. A. ( Site 2902), Monterrey, Nuevo Leon, 64460, Mexico\|Cuidados Oncologicos ( Site 2908), Santiago De Quetaro, Queretaro, 76000, Mexico\|Centro de Estudios de Investigacion Metabolicos y Cardiovasculares ( Site 2901), Madero, Tamaulipas, 89440, Mexico\|Centro Estatal de Cancerologia de Chihuahua ( Site 2907), Chihuahua, 31000, Mexico\|CRYPTEX Investigacion Clinica S.A. de C.V. ( Site 2900), Mexico City, 06100, Mexico\|CENEIT Oncologicos ( Site 2904), Mexico, 03100, Mexico\|Oaxaca Site Management Organization S.C. ( Site 2905), Oaxaca, 68000, Mexico\|Hospital de Alta Complejidad de La Libertad Virgen de La Puerta ( Site 3102), Trujillo, La Libertad, 13006, Peru\|Instituto Nacional de Enfermedades Neoplasicas ( Site 3106), Lima, Muni Metro De Lima, 15038, Peru\|Hospital Nacional Guillermo Almenara Irigoyen ( Site 3107), Lima, 15033, Peru\|Clinica Internacional Sede San Borja ( Site 3100), Lima, 15036, Peru\|Instituto de Oncologia y Radioterapia Clinica Ricardo Palma ( Site 3101), Lima, 15036, Peru\|Oncosalud-Clinical Research ( Site 3108), Lima, 15036, Peru\|Hospital Central de la Fuerza Aerea del Peru ( Site 3104), Lima, 15046, Peru\|Hospital Militar Central Coronel Luis Arias Schereiber ( Site 3105), Lima, 15076, Peru\|Hospital Arzobispo Loayza ( Site 3103), Lima, 15082, Peru\|S.C. Pelican Impex S.R.L Spitalul Clinic Pelican Oradea ( Site 1102), Oradea, Bihor, 410469, Romania\|Medisprof ( Site 1107), Cluj Napoca, Cluj, 400641, Romania\|SC Radiotherapy Center Cluj SRL ( Site 1105), Comuna Floresti, Cluj, 407280, Romania\|S.C. Centrul de Oncologie Sf. Nectarie SRL ( Site 1103), Craiova, Dolj, 200542, Romania\|Spitalul PDR Medlife ( Site 1106), Brasov, 500152, Romania\|S.C.Focus Lab Plus S.R.L ( Site 1101), Bucuresti, 022548, Romania\|S.C.Gral Medical S.R.L ( Site 1104), Bucuresti, 031422, Romania\|Arkhangelsk Clinical Oncological Dispensary ( Site 1204), Arkhangelsk, Arkhangel Skaya Oblast, 163045, Russian Federation\|Chelyabinsk Regional Clinical Oncological Dispensary ( Site 1212), Chelyabinsk, Chelyabinskaya Oblast, 454087, Russian Federation\|MEDSI Clinical Hospital on Pyatnitsky Highway-Departmentof Antitumor Drug therapy ( Site 1216), Krasnogorsk, Moskovskaya Oblast, 143442, Russian Federation\|N.N. Blokhin NMRCO ( Site 1201), Moscow, Moskva, 115477, Russian Federation\|MSROI named after P.A. Hertsen branch of FSBI NMRC Radiology ( Site 1213), Moscow, Moskva, 125284, Russian Federation\|Ryazan Regional Clinical Oncology dispensary ( Site 1202), Ryazan, Ryazanskaya Oblast, 390011, Russian Federation\|SBHI Samara Regional Clinical Oncology Dispensary ( Site 1211), Samara, Samarskaya Oblast, 443031, Russian Federation\|Scientific Research Oncology Institute n.a. N.N.Petrov ( Site 1208), Saint Petersburg, Sankt-Peterburg, 197758, Russian Federation\|Clinical Hospital Saint Luka ( Site 1205), Saint-Petersburg, Sankt-Peterburg, 194044, Russian Federation\|SBHI Leningrad Regional Clinical Hospital ( Site 1206), St.Petersburg, Sankt-Peterburg, 194291, Russian Federation\|Republican Clinical Oncology Dispensary of Tatarstan MoH named after professor M.Z. Sigal ( Site 120, Kazan, Tatarstan, Respublika, 420029, Russian Federation\|Hospital Universitario Quiron Madrid ( Site 1352), Pozuelo de Alarcon, Madrid, 28223, Spain\|Hospital Universitari Vall d Hebron ( Site 1350), Barcelona, 08035, Spain\|Universitaetsspital Zuerich ( Site 1400), Zuerich, Aargau, 8091, Switzerland\|Hopitaux Universitaires de Geneve HUG. ( Site 1406), Geneva, Geneve, 1211, Switzerland\|Ospedale Regionale di Bellinzona e Valli ( Site 1407), Bellinzona, Ticino, 6500, Switzerland\|Necmettin Erbakan Universitesi Meram Tip Fakultesi ( Site 1507), Konya, Adana, 42080, Turkey\|Baskent University Adana Training Hospital ( Site 1508), Adana, 01250, Turkey\|Hacettepe Universitesi T?p Fakultesi ( Site 1503), Ankara, 06100, Turkey\|Akdeniz Universitesi Tip Fakultesi ( Site 1504), Antalya, 07070, Turkey\|Trakya Universitesi Tip Fakultesi ( Site 1500), Edirne, 22030, Turkey\|Istanbul Universitesi Cerrahpasa Tip Fakultesi ( Site 1505), Istanbul, 34098, Turkey\|G?ztepe Prof. Dr. Süleyman Yal??n ?ehir Hastanesi-oncology ( Site 1506), Istanbul, 34722, Turkey\|Ege Universitesi Tip Fakultesi ( Site 1502), Izmir, 35100, Turkey\|Churchill Hospital ( Site 1606), Oxford, Worcestershire, OX3 7LE, United Kingdom\|Christie NHS Foundation Trust ( Site 1601), Manchester, M20 4BX, United Kingdom\|Northern Centre for Cancer Care ( Site 1602), Newcastle Upon Tyne, NE7 7DN, United Kingdom\|Weston Park Hospital ( Site 1607), Sheffield, S10 2SJ, United Kingdom Less <<
NCT03205761	Advanced Breast Cancer	PHASE2	COMPLETED	2022-12-15	Hospital Universitario Germans... More >> Trias i Pujol, Badalona, Barcelona, 08916, Spain\|Hospital Universitario San Joan de Reus, Reus, Tarragona, 43204, Spain\|Hospital del Mar, Barcelona, 08003, Spain\|Hospital Universitario Vall d′Hebron, Barcelona, 08035, Spain\|Hospital Clinic i Provincial, Barcelona, 08036, Spain\|Hospital de la Santa Creu i Sant Pau, Barcelona, 08041, Spain\|Complejo Hospitalario Universitario Reina Sofía, Cordoba, 14005, Spain\|Hospital San Pedro de Alcántara, Cáceres, 10003, Spain\|Hospital General Universitario Gregorio Mara?ón, Madrid, 28007, Spain\|Centro Oncológico MD Anderson International Espa?a, Madrid, 28033, Spain\|Hospital Universitario Puerta de Hierro Majadahonda, Madrid, 28222, Spain\|Hospital Universitario Virgen de la Macarena, Sevilla, 41009, Spain\|Instituto Valenciano de Oncología (IVO), Valencia, 46009, Spain\|Hospital Clínico Universitario de Valencia, Valencia, 46010, Spain\|Hospital Clínico Universitario de Zaragoza "Lozano Blesa", Zaragoza, 50006, Spain\|Hospital Universitario Miguel Servet, Zaragoza, 50009, Spain Less <<
NCT03286842	HER2-ve Metastatic Breast Canc... More >>er\|Germline BRCA1/2 Mutations\|Somatic BRCA1/2 Mutations Less <<	PHASE3	COMPLETED	2021-10-08	Research Site, Towson, Marylan... More >>d, 21204, United States\|Research Site, Jackson, Mississippi, 39202, United States\|Research Site, Plovdiv, 4004, Bulgaria\|Research Site, Sofia, 1303, Bulgaria\|Research Site, Sofia, 1330, Bulgaria\|Research Site, Varna, 9000, Bulgaria\|Research Site, Vancouver, British Columbia, V5Z 4E6, Canada\|Research Site, Toronto, Ontario, M4N 3M5, Canada\|Research Site, Quebec City, Quebec, G1S 4L8, Canada\|Research Site, Angers Cedex 02, 49055, France\|Research Site, Avignon, 84000, France\|Research Site, Besan?on, 25000, France\|Research Site, Bordeaux, 33076, France\|Research Site, Caen cedex 05, 14076, France\|Research Site, Le Mans, 72000, France\|Research Site, Lille, 59000, France\|Research Site, Limoges, 87042, France\|Research Site, Lorient cedex, 56322, France\|Research Site, Marseille, 13273, France\|Research Site, Montpellier, 34070, France\|Research Site, Nancy, 54100, France\|Research Site, Nantes, 44202, France\|Research Site, Paris, 75475, France\|Research Site, Paris, 75908, France\|Research Site, Pierre benite, 69495, France\|Research Site, Plerin SUR MER, 22190, France\|Research Site, Rennes, 35042, France\|Research Site, Rouen, 76021, France\|Research Site, Saint-quentin Cedex, 02321, France\|Research Site, St Herblain, 44805, France\|Research Site, Toulouse Cedex 9, 31059, France\|Research Site, Dresden, 1307, Germany\|Research Site, Erlangen, 91054, Germany\|Research Site, Essen, 45130, Germany\|Research Site, Essen, 45147, Germany\|Research Site, Hannover, 30625, Germany\|Research Site, K?ln, 50931, Germany\|Research Site, München, 80637, Germany\|Research Site, München, 81675, Germany\|Research Site, Münster, 48149, Germany\|Research Site, Rostock, 18059, Germany\|Research Site, Budapest, 1032, Hungary\|Research Site, Budapest, 1083, Hungary\|Research Site, Aviano, 33081, Italy\|Research Site, Bologna, 40138, Italy\|Research Site, Candiolo, 10060, Italy\|Research Site, Catania, 95122, Italy\|Research Site, Genova, 16132, Italy\|Research Site, Milano, 20132, Italy\|Research Site, Napoli, 80131, Italy\|Research Site, Padova, 35128, Italy\|Research Site, Perugia, 06132, Italy\|Research Site, Prato, 59100, Italy\|Research Site, Roma, 00144, Italy\|Research Site, Roma, 00161, Italy\|Research Site, Roma, 00189, Italy\|Research Site, Rozzano, 20089, Italy\|Research Site, Nagoya-shi, 464-8681, Japan\|Research Site, Shinagawa-ku, 142-8666, Japan\|Research Site, Suita-shi, 565-0871, Japan\|Research Site, Daegu, 41404, Korea, Republic of\|Research Site, Goyang-si, 10408, Korea, Republic of\|Research Site, Incheon, 21565, Korea, Republic of\|Research Site, Seongnam, 13620, Korea, Republic of\|Research Site, Seoul, 03080, Korea, Republic of\|Research Site, Seoul, 03722, Korea, Republic of\|Research Site, Seoul, 135-710, Korea, Republic of\|Research Site, Gdańsk, 80-214, Poland\|Research Site, Gliwice, 44-101, Poland\|Research Site, Grzepnica, 72-003, Poland\|Research Site, Lublin, 20-090, Poland\|Research Site, Poznan, 61-866, Poland\|Research Site, Szczecin, 70-111, Poland\|Research Site, Warszawa, 02-781, Poland\|Research Site, Wroclaw, 53-413, Poland\|Research Site, Irkutsk, 664035, Russian Federation\|Research Site, Kazan, 420029, Russian Federation\|Research Site, Moscow, 115478, Russian Federation\|Research Site, Omsk, 644013, Russian Federation\|Research Site, Ryazan, 390011, Russian Federation\|Research Site, Samara, 443031, Russian Federation\|Research Site, Sankt-Peterburg, 197758, Russian Federation\|Research Site, St.Petersburg, 191014, Russian Federation\|Research Site, Surgut, 628408, Russian Federation\|Research Site, Ufa, 450054, Russian Federation\|Research Site, Alicante, 03550, Spain\|Research Site, Barcelona, 08036, Spain\|Research Site, Cáceres, 10003, Spain\|Research Site, Granada, 18014, Spain\|Research Site, L'Hospitalet De Llobregat, 08907, Spain\|Research Site, Madrid, 08035, Spain\|Research Site, Madrid, 28040, Spain\|Research Site, Madrid, 28050, Spain\|Research Site, Majadahonda, 28222, Spain\|Research Site, Pamplona, 31008, Spain\|Research Site, San Cristóbal de La Laguna, 38320, Spain\|Research Site, Sevilla, 41009, Spain\|Research Site, Sevilla, 41013, Spain\|Research Site, Vigo, 36312, Spain\|Research Site, Zaragoza, 50009, Spain\|Research Site, Kaohsiung, 80756, Taiwan\|Research Site, Taichung, 40447, Taiwan\|Research Site, Taipei, 10048, Taiwan\|Research Site, Taipei, 11217, Taiwan\|Research Site, Taoyuan City, 333, Taiwan\|Research Site, Adana, 01120, Turkey\|Research Site, Adana, 01130, Turkey\|Research Site, Ankara, 06230, Turkey\|Research Site, Istanbul, 34390, Turkey\|Research Site, Izmir, 35575, Turkey\|Research Site, Kayseri, 38039, Turkey\|Research Site, Konya, 42080, Turkey\|Research Site, Mersin, 33343, Turkey\|Research Site, Tekirdag, 59100, Turkey\|Research Site, Cardiff., CF14 2TL, United Kingdom\|Research Site, Colchester, CO4 5JL, United Kingdom\|Research Site, Edinburgh, EH4 2XR, United Kingdom\|Research Site, Glasgow, G12 0YN, United Kingdom\|Research Site, Leeds, LS9 7TF, United Kingdom\|Research Site, London, SE1 9RT, United Kingdom\|Research Site, London, SW3 6JJ, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom\|Research Site, Sutton, SM2 5PT, United Kingdom Less <<
NCT02476968	BRCA or HRR+ Mutated Ovarian C... More >>ancer Patients Less <<	PHASE4	COMPLETED	2021-12-17	Research Site, Plovdiv, 4000, ... More >>Bulgaria\|Research Site, Plovdiv, 4004, Bulgaria\|Research Site, Sofia, 1303, Bulgaria\|Research Site, Sofia, 1330, Bulgaria\|Research Site, Sofia, 1407, Bulgaria\|Research Site, Sofia, 1756, Bulgaria\|Research Site, Varna, 9010, Bulgaria\|Research Site, Calgary, Alberta, T2N 4N2, Canada\|Research Site, Halifax, Nova Scotia, B3H 2E2, Canada\|Research Site, London, Ontario, N6A 4L6, Canada\|Research Site, Toronto, Ontario, M5G 1X6, Canada\|Research Site, Montreal, Quebec, H2X 0A9, Canada\|Research Site, Montreal, Quebec, H3T 1E2, Canada\|Research Site, Brno, 625 00, Czechia\|Research Site, Brno, 656 53, Czechia\|Research Site, Novy Jicin, 741 01, Czechia\|Research Site, Olomouc, 775 20, Czechia\|Research Site, Ostrava, 708 52, Czechia\|Research Site, Praha 2, 128 08, Czechia\|Research Site, Praha 5, 15000, Czechia\|Research Site, Budapest, 1032, Hungary\|Research Site, Budapest, 1062, Hungary\|Research Site, Budapest, 1122, Hungary\|Research Site, Debrecen, 4032, Hungary\|Research Site, Kecskemét, 6000, Hungary\|Research Site, Nyíregyháza, 4400, Hungary\|Research Site, Bari, 70124, Italy\|Research Site, Milano, 20141, Italy\|Research Site, Napoli, 80131, Italy\|Research Site, Perugia, 06132, Italy\|Research Site, Bialystok, 15-027, Poland\|Research Site, Gdansk, 80-402, Poland\|Research Site, Kielce, 25-734, Poland\|Research Site, Poznan, 60-569, Poland\|Research Site, Poznań, Poland\|Research Site, Badalona, 08916, Spain\|Research Site, Barcelona, 08025, Spain\|Research Site, Burgos, 09006, Spain\|Research Site, L'Hospitalet de Llobregat, 08908, Spain\|Research Site, Madrid, 28040, Spain\|Research Site, Madrid, 28041, Spain\|Research Site, San Cristobal de La Laguna, 38320, Spain\|Research Site, Sevilla, 41009, Spain\|Research Site, Valencia, 46010, Spain\|Research Site, Valencia, 46026, Spain\|Research Site, Zaragoza, 50009, Spain\|Research Site, Belfast, BT9 7AB, United Kingdom\|Research Site, Birmingham, B18 7QH, United Kingdom\|Research Site, Cardiff, CF14 2TL, United Kingdom\|Research Site, Glasgow, G12 OYN, United Kingdom\|Research Site, Leeds, LS9 7TF, United Kingdom\|Research Site, London, SE1 9RT, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom\|Research Site, Newcastle upon Tyne, NE7 7DN, United Kingdom\|Research Site, Oxford, OX3 7LJ, United Kingdom\|Research Site, Swansea, SA2 8QA, United Kingdom\|Research Site, Taunton, TA1 5DA, United Kingdom\|Research Site, Wirral, CH63 4JY, United Kingdom Less <<
NCT03534492	Bladder Cancer	Phase 2	Not yet recruiting	March 2020	Spain ... More >> Hospital Universitario Central de Asturias Not yet recruiting Oviedo, Asturias, Spain, 33006 Contact: Carlos Álvarez, MD Principal Investigator: Carlos Álvarez, MD ICO Badalona Not yet recruiting Badalona, Barcelona, Spain, 08916 Contact: Albert Font, MD Principal Investigator: Albert Font, MD Clinica IMQ Zorrotzaurre Not yet recruiting Bilbao, Spain Contact: Ricardo Fernández-Rodríguez, MD Principal Investigator: Ricardo Fernández-Rodríguez, MD Hospital San Pedro de Alcántara Not yet recruiting Cáceres, Spain Contact: Ricardo Collado-Martín, MD Principal Investigator: Ricardo Collado-Martín, MD Hospital Universitario Lucus Augusti Not yet recruiting Lugo, Spain, 27003 Contact: Sergio Vázquez, MD Principal Investigator: Sergio Vázquez, MD Hospital Ramón Y Cajal Not yet recruiting Madrid, Spain, 28034 Contact: Pablo Gajate, MD Principal Investigator: Pablo Gajate, MD Hospital Universitario 12 de Octubre Not yet recruiting Madrid, Spain, 28041 Contact: Guillermo de Velasco, MD Principal Investigator: Guillermo de Velasco, MD Hopsital Universitario Madrid Sanchinarro (CIOCC) Not yet recruiting Madrid, Spain Contact: Juan F Rodríguez, MD Principal Investigator: Juan F Rodríguez, MD Hospital Virgen Macarena Not yet recruiting Sevilla, Spain Contact: Juan A Virizuela, MD Principal Investigator: Juan A Virizuela, MD Hospital La Fe Not yet recruiting Valencia, Spain Contact: José Muñoz-Langa, MD Principal Investigator: José Muñoz-Langa, MD Less <<
NCT03047135	Prostate	PHASE2	ACTIVE_NOT_RECRUITING	2025-05-01	Johns Hopkins Hospital, Baltim... More >>ore, Maryland, 21231, United States\|University of Nebraska Medical Center, Omaha, Nebraska, 68198, United States\|Thomas Jefferson University, Philadelphia, Pennsylvania, 19107, United States\|Allegheny Cancer Center, Pittsburgh, Pennsylvania, 15212, United States Less <<
NCT01562210	NSCLC	Phase 1	Recruiting	March 2020	Netherlands ... More >> Netherlands Cancer Institute - Antoni van Leeuwenhoek Ziekenhuis (NKI-AVL) Recruiting Amsterdam, Noord-Holland, Netherlands, 1066 CX Principal Investigator: M. M. van den Heuvel, MD, PhD Principal Investigator: M. Verheij, MD, PhD Less <<
NCT03534453	Relapsed Ovarian Cancer ... More >> Following Complete or Partial Response to Platinum Based Chemotherapy Platinum Sensitive Less <<	Phase 3	Recruiting	March 1, 2022	China ... More >> Research Site Not yet recruiting Beijing, China, 100021 Research Site Not yet recruiting Beijing, China, 100044 Research Site Recruiting Beijing, China, 100142 Research Site Not yet recruiting Beijing, China, 100730 Research Site Recruiting Changsha, China, 410013 Research Site Recruiting Chengdu, China, 610041 Research Site Recruiting Chongqing, China, 400030 Research Site Not yet recruiting ChongQing, China, 400038 Research Site Not yet recruiting Guangzhou, China, 510060 Research Site Recruiting Hangzhou, China, 310006 Research Site Recruiting Hangzhou, China, 310022 Research Site Recruiting Harbin, China, 150081 Research Site Recruiting Hefei, China Research Site Not yet recruiting Jinan, China, 250012 Research Site Not yet recruiting Nanjing, China, 210009 Research Site Recruiting Shanghai, China, 200011 Research Site Recruiting Shanghai, China, 200032 Research Site Recruiting Shanghai, China, 200080 Research Site Recruiting Shenyang, China, 110016 Research Site Recruiting Tianjin, China, 300060 Research Site Recruiting Tianjin, China Research Site Recruiting Wuhan, China, CN-430030 Research Site Not yet recruiting Xi'an, China Research Site Recruiting Xian, China, 710061 India Research Site Not yet recruiting Ahmedabad, India, 380009 Research Site Not yet recruiting Mumbai, India, 400012 Research Site Not yet recruiting Mumbai, India, 400053 Research Site Not yet recruiting New Delhi, India, 11029 Research Site Not yet recruiting Pune, India, 411001 Research Site Not yet recruiting Vellore, India, 632004 Less <<
NCT03344965	Metastatic Breast Cancer\|Invas... More >>ive Breast Cancer\|Somatic Mutation Breast Cancer (BRCA1)\|Somatic Mutation Breast Cancer (BRCA2)\|CHEK2 Gene Mutation\|ATM Gene Mutation\|PALB2 Gene Mutation\|RAD51 Gene Mutation\|BRIP1 Gene Mutation\|NBN Gene Mutation Less <<	PHASE2	ACTIVE_NOT_RECRUITING	2025-12-30	University of Alabama at Birmi... More >>ngham, Birmingham, Alabama, 35294, United States\|University of California, San Francisco, San Francisco, California, 94143, United States\|University of Chicago, Chicago, Illinois, 60637, United States\|Indiana University, Indianapolis, Indiana, 46202, United States\|Johns Hopkins University, Baltimore, Maryland, 21218, United States\|Beth Israel Deaconess Medical Center, Boston, Massachusetts, 02115, United States\|Brigham and Women's Hospital, Boston, Massachusetts, 02115, United States\|Dana-Farber Cancer Institute, Boston, Massachusetts, 02215, United States\|Memorial Sloan Kettering Cancer Center Basking Ridge, Basking Ridge, New Jersey, 07920, United States\|Memorial Sloan Kettering Cancer Center Monmouth, Middletown, New Jersey, 07748, United States\|Memorial Sloan Kettering Cancer Center Bergen, Montvale, New Jersey, 07645, United States\|Memorial Sloan Kettering Cancer Center Commack, Commack, New York, 11725, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States\|Memorial Sloan Kettering Cancer Center Nassau, Uniondale, New York, 11553, United States\|Memorial Sloan Kettering Cancer Center Westchester, West Harrison, New York, 10604, United States\|Duke University, Durham, North Carolina, 27708, United States\|UPMC Hillman Cancer Center - Erie, Erie, Pennsylvania, 16505, United States\|University of Pennsylvania, Philadelphia, Pennsylvania, 19104, United States\|University of Pittsburgh, Pittsburgh, Pennsylvania, 15260, United States\|University of Washington Fred Hutchinson Cancer Care, Seattle, Washington, 98109, United States Less <<
NCT03402841	Non-Germline BRCA Mutated Ovar... More >>ian Cancer Less <<	PHASE3	COMPLETED	2022-03-10	Research Site, Graz, 8036, Aus... More >>tria\|Research Site, Innsbruck, 6020, Austria\|Research Site, Vienna, 1090, Austria\|Research Site, Wein, 1130, Austria\|Research Site, Bruxelles, 1200, Belgium\|Research Site, Leuven, 3000, Belgium\|Research Site, Loverval, 6280, Belgium\|Research Site, Namur, 5000, Belgium\|Research Site, Wilrijk, 2610, Belgium\|Research Site, Plovdiv, 4000, Bulgaria\|Research Site, Plovdiv, 4004, Bulgaria\|Research Site, Sofia, 1330, Bulgaria\|Research Site, Victoria, British Columbia, V8R 6V5, Canada\|Research Site, London, Ontario, N6A 5W9, Canada\|Research Site, Ottawa, Ontario, K1H 8L6, Canada\|Research Site, Toronto, Ontario, M5G2M9, Canada\|Research Site, Montreal, Quebec, H2X 0A9, Canada\|Research Site, Sherbrooke, Quebec, J1H 5N4, Canada\|Research Site, Brno, 625 00, Czechia\|Research Site, Novy Jicin, 74101, Czechia\|Research Site, Olomouc, 775 20, Czechia\|Research Site, Ostrava, 708 52, Czechia\|Research Site, Praha 2, 128 08, Czechia\|Research Site, Arhus, 8200, Denmark\|Research Site, ?lborg, 9100, Denmark\|Research Site, Kuopio, 70210, Finland\|Research Site, Oulu, 90029, Finland\|Research Site, Tampere, 33520, Finland\|Research Site, Afula, 18101, Israel\|Research Site, Beer Sheva, Israel\|Research Site, Haifa, 91096, Israel\|Research Site, Jerusalem, 91031, Israel\|Research Site, Kfar Saba, 4428164, Israel\|Research Site, Ramat Gan, 52621, Israel\|Research Site, Ancona, 60020, Italy\|Research Site, Brescia, 25123, Italy\|Research Site, Lecco, 23900, Italy\|Research Site, Milano, 20141, Italy\|Research Site, Padova, 35128, Italy\|Research Site, Torino, 10126, Italy\|Research Site, Torino, 10128, Italy\|Research Site, Breda, 4818 CK, Netherlands\|Research Site, Tilburg, 5022 GC, Netherlands\|Research Site, Bergen, 5053, Norway\|Research Site, Oslo, 424, Norway\|Research Site, Gdynia, 81-519, Poland\|Research Site, Kraków, 31-501, Poland\|Research Site, Lublin, 20-090, Poland\|Research Site, Olsztyn, 10-513, Poland\|Research Site, Poznań, 60-569, Poland\|Research Site, Warszawa, 02-781, Poland\|Research Site, Warszawa, 04-141, Poland\|Research Site, Coimbra, 3000-073, Portugal\|Research Site, Lisboa, 1400-048, Portugal\|Research Site, Bucuresti, 031422, Romania\|Research Site, Cluj Napoca, 400058, Romania\|Research Site, Cluj-Napoca, 400015, Romania\|Research Site, Ljubljana, 1000, Slovenia\|Research Site, Badalona, 08916, Spain\|Research Site, Barcelona, 08036, Spain\|Research Site, Barcelona, 08041, Spain\|Research Site, Barcelona, 8035, Spain\|Research Site, Córdoba, 14004, Spain\|Research Site, Girona, 17007, Spain\|Research Site, Hospitalet deLlobregat, 08907, Spain\|Research Site, Madrid, 28027, Spain\|Research Site, Madrid, 28046, Spain\|Research Site, Málaga, 29011, Spain\|Research Site, Pamplona, 31008, Spain\|Research Site, Sevilla, 41009, Spain\|Research Site, Valencia, 46009, Spain\|Research Site, Valencia, 46026, Spain\|Research Site, Link?ping, 581 85, Sweden\|Research Site, Lund, 221 85, Sweden\|Research Site, Basel, 4031, Switzerland\|Research Site, Bellinzona, 6500, Switzerland\|Research Site, Bern, 3010, Switzerland\|Research Site, Frauenfeld, 8501, Switzerland\|Research Site, Genève 14, 1205, Switzerland\|Research Site, Lausanne, 1011, Switzerland\|Research Site, Zürich, 8091, Switzerland\|Research Site, Aberdeen, AB25 2ZN, United Kingdom\|Research Site, Colchester, CO4 5JL, United Kingdom\|Research Site, Exeter, EX2 5DW, United Kingdom\|Research Site, Leeds, LS9 7TF, United Kingdom\|Research Site, Leicester, LE1 5WW, United Kingdom\|Research Site, London, SE1 9RT, United Kingdom\|Research Site, London, WC1N 3BG, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom\|Research Site, Northampton, NN1 5BD, United Kingdom\|Research Site, Scarborough, YO12 6QL, United Kingdom Less <<
NCT02533765	Neoplasms, Germ Cell and Embry... More >>onal Less <<	PHASE2	COMPLETED	2023-02-13	U.O Oncologia Medica, IRST IRC... More >>CS, Meldola, FC, 47014, Italy\|Istituto Nazionale Tumori IRCCS "Fondazione G.Pascale", Napoli, 80131, Italy Less <<
NCT03434158	Prostate Cancer Metastatic	PHASE2	COMPLETED	2022-05-12	Complexo Hospitalario Universi... More >>tario de Santiago, Santiago De Compostela, A Coru?a, 15706, Spain\|Hospital Universitario Central de Asturias, Oviedo, Asturias, 33011, Spain\|ICO L'Hospitalet, L'Hospitalet De Llobregat, Barcelona, 08908, Spain\|Hospital Clínic de Barcelona, Barcelona, 08036, Spain\|Complejo Hospitalario Regional Reina Sofía, Córdoba, 14004, Spain\|Hospital Universitario 12 de Octubre, Madrid, 28041, Spain\|Fundación Instituto Valenciano de Oncología, Valencia, 46009, Spain\|Hospital Universitario i Politècnic La Fe, Valencia, 46026, Spain Less <<
NCT02677038	Metastatic Pancreatic Adenocar... More >>cinoma\|Pancreatic Ductal Adenocarcinoma\|Stage IV Pancreatic Cancer AJCC v6 and v7 Less <<	PHASE2	COMPLETED	2022-07-18	M D Anderson Cancer Center, Ho... More >>uston, Texas, 77030, United States Less <<
NCT02855697	Ovarian Cancer	Early Phase 1	Recruiting	December 2020	United Kingdom ... More >> The Christie NHS Foundation Trust Recruiting Manchester, United Kingdom, M20 4BX Contact: Andrew Clamp, MD, PhD 0161 446 3606 Andrew.Clamp@christie.nhs.uk Contact: Catherine Rogers, Nurse 0161 918 7689 catherine.rogers@christie.nhs.uk Principal Investigator: Andrew Clamp Less <<
NCT03448718	Metastatic Urothelial Cancer	PHASE2	COMPLETED	2021-10-15	University of Chicago Medical ... More >>Center, Chicago, Illinois, 60637, United States\|Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, Maryland, 21287, United States\|Karmanos Cancer Center (Wyane State University), Detroit, Michigan, 48201, United States\|Icahn School of Medicine at Mount Sinai, New York, New York, 10029-6542, United States\|University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, 27599, United States\|Vanderbilt-Ingran Cancer Center, Nashville, Tennessee, 37232, United States\|Huntsman Cancer Institute University of Utah, Salt Lake City, Utah, 84112-5550, United States Less <<
NCT03109080	Breast Neoplasms, Triple-Negat... More >>ive Breast Neoplasm Malignant Female Radiotherapy Side Effect Less <<	Phase 1	Recruiting	July 2021	France ... More >> Institut Curie Recruiting Paris, France, 75005 Contact: Youlia KIROVA, MD Less <<
NCT03367689	Breast Cancer	PHASE2	TERMINATED	2021-12-31	Hospital del Mar, Barcelona, S... More >>pain\|Onkologikoa, Donostia, Spain\|Institut Català d' Oncologia L'Hospitalet (ICO), L'Hospitalet De Llobregat, Spain\|Hospital Ramón y Cajal, Madrid, Spain\|Hospital Arnau de Vilanova de Valencia, Valencia, Spain Less <<
NCT02645149	Melanoma	Phase 4	Not yet recruiting	August 2021	Australia, New South Wales ... More >> Royal Prince Alfred Hospital Not yet recruiting Camperdown, New South Wales, Australia, 2050 Contact: Maria Gonzalez 612 9911 7200 maria.gonzalez@melanoma.org.au Principal Investigator: John Thompson Westmead Hospital Westmead, New South Wales, Australia, 2145 Melanoma Institute Australia Not yet recruiting Wollstonecraft, New South Wales, Australia, 2065 Contact: Maria Gonzalez +612 9911 7200 maria.gonzalez@melanoma.org.au Contact: Alex Menzies +612 9911 7200 info@melanoma.org.au Sub-Investigator: Georgina Long Principal Investigator: Alex Menzies Less <<
NCT03297606	Lymphoma, Non-Hodgkin ... More >> Multiple Myeloma Advanced Solid Tumors Less <<	Phase 2	Recruiting	September 2021	Canada, British Columbia ... More >> BCCA - Vancouver Cancer Centre Recruiting Vancouver, British Columbia, Canada, V5Z 4E6 Contact: Daniel John Renouf 604 877-6000 ext 672357 Canada, Ontario London Regional Cancer Program Recruiting London, Ontario, Canada, N6A 5W9 Contact: Stephen Welch 519 685-8640 Ottawa Hospital Research Institute Recruiting Ottawa, Ontario, Canada, K1H 8L6 Contact: John Hilton 613 737-7700 ext 70179 University Health Network Recruiting Toronto, Ontario, Canada, M5G 2M9 Contact: Lillian Siu 416 946-2911 Canada, Quebec The Jewish General Hospital Recruiting Montreal, Quebec, Canada, H3T 1E2 Contact: Cristiano Ferrario 514 398-8307 Less <<
NCT02624973	Breast Cancer	Phase 2	Active, not recruiting	June 2030	Norway ... More >> Akershus University Hospital Lørenskog, Akershus, Norway Haukeland University Hospital Bergen, Hordaland, Norway, 5021 Helse Fonna Haugesund, Rogaland, Norway Helse Stavanger Stavanger, Rogaland, Norway Helse Førde Førde, Sogn Og Fjordande, Norway St. Olavs Hospital Trondheim, Sør Trøndelag, Norway Helse Nord/UNN Tromsø, Troms, Norway Less <<
NCT03498521	Cancer of Unknown Primary Site	Phase 2	Recruiting	April 16, 2022	-
NCT02338622	Advanced Cancer	Phase 1	Unknown	October 2015	United Kingdom ... More >> Northern Institute for Cancer, Freeman Hospital Recruiting Newcastle, Newcastle upon Tyne, United Kingdom, NE7 7DN Contact: Elizabeth R Plummer, MD +44(0)191 213844 ruth.plummer@newcastle.ac.uk Principal Investigator: Elizabeth R Plummer, MD Royal Marsden NHS Foundation Trust Recruiting Sutton, Surrey, United Kingdom, SM2 5PT Contact: Timothy A Yap, PhD 0208 661 3539 timothy.yap@icr.ac.uk Principal Investigator: Timothy A Yap, PhD Less <<
NCT03251612	Colorectal Cancer Metastatic	Phase 2	Recruiting	December 2020	Denmark ... More >> Department of Oncology, Aalborg University Hospital Not yet recruiting Aalborg, Denmark Contact: Mette Yilmaz, MD m.yilmaz@rn.dk Department of Oncology, Rigshospitalet Not yet recruiting Copenhagen, Denmark Contact: Lone N Petersen, MD Lone.Noergaard.Petersen@regionh.dk Departmen of Oncology, Vejle Hospital Recruiting Vejle, Denmark Contact: Lars H Jensen, MD lars.henrik.jensen@rsyd.dk Germany Universitätsklinikum Hamburg - Eppendorf, Universitäres Cancer Center Hamburg (UCCH) Not yet recruiting Hamburg, Germany Contact: Andreas Block, MD block@uke.de Less <<
NCT01042379	Breast Neoplasms ... More >> Breast Cancer Breast Tumors Less <<	Phase 2	Recruiting	-	-
NCT03155620	Advanced Malignant Solid Neopl... More >>asm Ann Arbor Stage III Childhood Non-Hodgkin Lymphoma Ann Arbor Stage IV Childhood Non-Hodgkin Lymphoma Childhood Langerhans Cell Histiocytosis Histiocytic Sarcoma Juvenile Xanthogranuloma Malignant Glioma Recurrent Central Nervous System Neoplasm Recurrent Childhood Ependymoma Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Medulloblastoma Recurrent Childhood Non-Hodgkin Lymphoma Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Ewing Sarcoma Recurrent Glioma Recurrent Hepatoblastoma Recurrent Langerhans Cell Histiocytosis Recurrent Malignant Solid Neoplasm Recurrent Neuroblastoma Recurrent Osteosarcoma Recurrent Peripheral Primitive Neuroectodermal Tumor Recurrent Rhabdoid Tumor Refractory Central Nervous System Neoplasm Refractory Childhood Malignant Germ Cell Tumor Refractory Ewing Sarcoma Refractory Glioma Refractory Hepatoblastoma Refractory Langerhans Cell Histiocytosis Refractory Malignant Solid Neoplasm Refractory Medulloblastoma Refractory Neuroblastoma Refractory Non-Hodgkin Lymphoma Refractory Osteosarcoma Refractory Peripheral Primitive Neuroectodermal Tumor Refractory Rhabdoid Tumor Refractory Rhabdomyosarcoma Rhabdoid Tumor Stage III Osteosarcoma AJCC v7 Stage III Soft Tissue Sarcoma AJCC v7 Stage IV Osteosarcoma AJCC v7 Stage IV Soft Tissue Sarcoma AJCC v7 Stage IVA Osteosarcoma AJCC v7 Stage IVB Osteosarcoma AJCC v7 Wilms Tumor Less <<	Phase 2	Recruiting	September 30, 2027	-
NCT05320757	Endometrial Cancer	EARLY_PHASE1	RECRUITING	2025-03-31	The University of Hong Kong, H... More >>ong Kong, Hong Kong Less <<
NCT05482074	Recurrent Metastatic Melanoma\|... More >>Cutaneous Melanoma\|Mucosal Melanoma\|Uveal Melanoma Less <<	PHASE2	WITHDRAWN	2027-05-01	-
NCT03782818	Pulmonary Arterial Hypertensio... More >>n Less <<	PHASE1\|PHASE2	RECRUITING	2025-03-24	University of Alberta Hospital... More >>, Edmonton, Alberta, T6G 2B7, Canada\|UHN-Toronto General Hospital, Toronto, Ontario, M5G 2C4, Canada\|IUCPQ-UL, Quebec City, Quebec, G1V4G5, Canada Less <<
NCT00494234	Breast Neoplasms	PHASE2	COMPLETED	2022-12-21	Research Site, West Hollywood,... More >> California, 90048, United States\|Research Site, Boston, Massachusetts, 02115, United States\|Research Site, Melbourne, 3000, Australia\|Research Site, Randwick, 2031, Australia\|Research Site, Duarte, CA, 91010, Canada\|Research Site, Kiel, 24105, Germany\|Research Site, K?ln, 50937, Germany\|Research Site, München, 81675, Germany\|Research Site, Tel-Aviv, 6423906, Israel\|Research Site, Hospitalet deLlobregat, 08907, Spain\|Research Site, Madrid, 08035, Spain\|Research Site, Lund, 221 85, Sweden\|Research Site, Cambridge, CB2 0QQ, United Kingdom\|Research Site, Edinburgh, EH4 2XR, United Kingdom\|Research Site, Fulham, SW3 6JJ, United Kingdom\|Research Site, London, SE1 9RT, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom Less <<
NCT04951492	Castration-Resistant Prostate ... More >>Carcinoma\|Prostate Adenocarcinoma Less <<	PHASE2	TERMINATED	2023-10-15	Fred Hutch/University of Washi... More >>ngton Cancer Consortium, Seattle, Washington, 98109, United States Less <<
NCT04515836	Mesothelioma\|Homologous Recomb... More >>ination Deficiency Less <<	PHASE2	RECRUITING	2025-04-15	University of Chicago Medical ... More >>Center, Chicago, Illinois, 60615, United States Less <<
NCT04330040	Ovarian Cancer\|Breast Cancer	PHASE4	COMPLETED	2022-09-30	Research Site, Ahmedabad, 3800... More >>09, India\|Research Site, Bhubaneswar, 751007, India\|Research Site, Chandigarh, 160012, India\|Research Site, Delhi, 110029, India\|Research Site, Faridabad, 121001, India\|Research Site, Guwahati, 781023, India\|Research Site, Kochi, 682041, India\|Research Site, Kolkata, 700099, India\|Research Site, Kolkata, 700160, India\|Research Site, Madurai, 625107, India\|Research Site, Mumbai, 400012, India\|Research Site, Mumbai, 400053, India\|Research Site, New Delhi, 110 085, India\|Research Site, New Delhi, 110005, India\|Research Site, New Delhi, 110063, India\|Research Site, Vellore, 632004, India Less <<
NCT05286827	Pancreatic Acinar Cell Carcino... More >>ma Less <<	PHASE2	RECRUITING	2025-06-01	National Institutes of Health ... More >>Clinical Center, Bethesda, Maryland, 20892, United States Less <<
NCT00633269	Neoplasm Metastasis	PHASE1	COMPLETED	2025-10-08	Research Site, London, United ... More >>Kingdom Less <<
NCT04236414	Solid Tumours	PHASE1	RECRUITING	2025-02-14	Research Site, Los Angeles, Ca... More >>lifornia, 90095, United States\|Research Site, Charlotte, North Carolina, 28203, United States\|Research Site, Cleveland, Ohio, 44106, United States\|Research Site, Charleston, South Carolina, 29401, United States\|Research Site, Clayton, 3168, Australia\|Research Site, Nedlands, 6009, Australia\|Research Site, Randwick, 2031, Australia\|Research Site, Wien, 1090, Austria\|Research Site, Natal, 59075-740, Brazil\|Research Site, Sao Paulo, 08270-070, Brazil\|Research Site, Edmonton, Alberta, T6G 2B7, Canada\|Research Site, Vancouver, British Columbia, V6H 3N1, Canada\|Research Site, Toronto, Ontario, M5G 1X8, Canada\|Research Site, Montreal, Quebec, H4A 3J1, Canada\|Research Site, K?benhavn ?, 2100, Denmark\|Research Site, Lille, 59000, France\|Research Site, Marseille, 13385, France\|Research Site, Paris, 75005, France\|Research Site, Toulouse, 31300, France\|Research Site, Villejuif Cedex, 94805, France\|Research Site, Heidelberg, 69120, Germany\|Research Site, Mainz, 55131, Germany\|Research Site, Budapest, 1094, Hungary\|Research Site, Haifa, 3109601, Israel\|Research Site, Petah Tikva, 4920235, Israel\|Research Site, Roma, 00165, Italy\|Research Site, Seoul, 03080, Korea, Republic of\|Research Site, Seoul, 05505, Korea, Republic of\|Research Site, Seoul, 06351, Korea, Republic of\|Research Site, Szczecin, 71-252, Poland\|Research Site, Warszawa, 01-211, Poland\|Research Site, Moscow, 117198, Russian Federation\|Research Site, Saint Petersburg, 197022, Russian Federation\|Research Site, Barcelona, 08035, Spain\|Research Site, Barcelona, 08950, Spain\|Research Site, Madrid, 28009, Spain\|Research Site, Madrid, 28046, Spain\|Research Site, Valencia, 46026, Spain\|Research Site, Dnipro, 49055, Ukraine\|Research Site, Lviv, 79035, Ukraine\|Research Site, Birmingham, B4 6NH, United Kingdom\|Research Site, Glasgow, G51 4TF, United Kingdom\|Research Site, Leeds, LS1 3EX, United Kingdom\|Research Site, Sutton, SM2 5PT, United Kingdom Less <<
NCT05522491	Solid Tumor	PHASE2	UNKNOWN	2024-09-01	-
NCT03829345	Oesophageal Cancer\|Gastro-Oeso... More >>phageal Junction Cancer\|Gastric Cancer Less <<	PHASE2	UNKNOWN	2022-02-14	Claire Saffery, Sutton, Surrey... More >>, SM2 5PT, United Kingdom\|Claire Saffery, Sutton, SM2 5PT, United Kingdom Less <<
NCT00679783	Ovarian Carcinoma\|Breast Cance... More >>r Less <<	PHASE2	COMPLETED	2022-07-20	Research Site, Edmonton, Alber... More >>ta, T6G 1Z2, Canada\|Research Site, Vancouver, British Columbia, V5Z 4E6, Canada\|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada\|Research Site, Hamilton, Ontario, L8V 5C2, Canada\|Research Site, Toronto, Ontario, M4N 3M5, Canada\|Research Site, Montreal, Quebec, H2X 3E4, Canada Less <<
NCT05340413	HER2-negative Breast Cancer\|Me... More >>tastatic Breast Cancer\|Triple Negative Breast Cancer Less <<	PHASE2	RECRUITING	2025-06-24	H Clinic de Barcelona, Barcelo... More >>na, Spain\|H Vall d Hebron, Barcelona, Spain\|H. San Cecilio, Granada, Spain\|H. 12 de Octubre, Madrid, Spain\|H. C. U. Valencia, Valencia, Spain Less <<
NCT06783127	Prostate Cancer\|Castrate Resis... More >>tant Prostate Cancer\|BRCA Mutation Less <<		RECRUITING	2026-12-31	Sabrina Rossetti, Napoli, Ital... More >>y\|Orazio Caffo, Trento, Italy Less <<
NCT04377087	Ovarian Cancer	PHASE2	TERMINATED	2023-05-31	Magee Women's Hospital of UPMC... More >>, Pittsburgh, Pennsylvania, 15213, United States Less <<
NCT04152941	Relapsed Ovarian Cancers Patie... More >>nts Less <<		COMPLETED	2020-02-11	ICO Paul Papin, Angers, 49055,... More >> France\|Institut Sainte-Catherine, Avignon, 84918, France\|CHRU Jean Minjoz, Besancon, 25030, France\|Clinique Tivoli, Bordeaux, 33000, France\|Institut Bergonié, Bordeaux, 33076, France\|Clinique Pasteur, Brest, 29200, France\|H?pital Morvan - Centre Hospitalier Universitaire, Brest, 29200, France\|Centre Jean Perrin, Clermont-ferrand, 63000, France\|Centre Georges Fran?ois Leclerc, Dijon, 21079, France\|Groupe Hospitalier Mutualiste de Grenoble, Grenoble, 38028, France\|Institut Hospitalier Franco-Britannique, Levallois Perret, 92300, France\|Centre Léon Bérard, Lyon, 69373, France\|ICM Val d'Aurelle, Montpellier, 34298, France\|ORACLE - Centre d'Oncologie de Gentilly, Nancy, 54100, France\|H?pital Privé du Confluent S.A.S., Nantes, 44277, France\|Centre Antoine Lacassagne, Nice, 6189, France\|Centre Hospitalier Régional d'Orléans, Orleans, 45067, France\|H?pital Saint-Louis, Paris, 75010, France\|H?pital Cochin, Paris, 75014, France\|Institut du Cancer Courlancy Reims, Reims, 51100, France\|Centre Eugène Marquis, Rennes, 35042, France\|Centre Hospitalier de Saint-Brieuc, Saint-brieuc, 22015, France\|ICO Centre René Gauducheau, Saint-herblain, 44805, France\|Clinique Mutualiste de l'Estuaire, Cité Sanitaire, Saint-nazaire, 44600, France\|Institut de Cancérologie Lucien Neuwirth, Saint-priest-en-jarez, 42271, France\|H?pitaux Universitaires de Strasbourg, Strasbourg, 67091, France\|ICL Institut de Cancérologie de Lorraine, Vand?uvre-lès-Nancy, 54511, France\|Gustave Roussy, Villejuif, 94805, France Less <<
NCT03786796	Renal Cell Carcinoma\|Metastati... More >>c Renal Cell Carcinoma\|Kidney Cancer\|Renal Carcinoma\|Kidney Cancer Metastatic Less <<	PHASE2	RECRUITING	2025-03-26	Johns Hopkins Sidney Kimmel Co... More >>mprehensive Cancer Center, Baltimore, Maryland, 21228, United States Less <<
NCT04421963	Ovarian Cancer\|Breast Cancer	PHASE3	ENROLLING_BY_INVITATION	2027-04-06	Research Site, West Hollywood,... More >> California, 90048, United States\|Research Site, Boca Raton, Florida, 33486, United States\|Research Site, Towson, Maryland, 21204, United States\|Research Site, Detroit, Michigan, 48201, United States\|Research Site, Minneapolis, Minnesota, 55407, United States\|Research Site, Basking Ridge, New Jersey, 07920, United States\|Research Site, Hackensack, New Jersey, 07601, United States\|Research Site, Bronx, New York, 10461, United States\|Research Site, New York, New York, 10032, United States\|Research Site, Philadelphia, Pennsylvania, 19104, United States\|Research Site, Pittsburgh, Pennsylvania, 15224, United States\|Research Site, Willow Grove, Pennsylvania, 19090, United States\|Research Site, Providence, Rhode Island, 02905, United States\|Research Site, Germantown, Tennessee, 38138, United States\|Research Site, Houston, Texas, 77030, United States\|Research Site, Leuven, 3000, Belgium\|Research Site, Namur, 5000, Belgium\|Research Site, Rio de Janeiro, 22793-080, Brazil\|Research Site, Plovdiv, 4000, Bulgaria\|Research Site, Plovdiv, 4004, Bulgaria\|Research Site, Sofia, 1330, Bulgaria\|Research Site, Halifax, Nova Scotia, B3H 1V7, Canada\|Research Site, Kingston, Ontario, K7L 2V7, Canada\|Research Site, Mississauga, Ontario, L5M 2N1, Canada\|Research Site, Ottawa, Ontario, K1H 8L6, Canada\|Research Site, Toronto, Ontario, M4N 3M5, Canada\|Research Site, Toronto, Ontario, M5G 2M9, Canada\|Research Site, Montreal, Quebec, H1T 2M4, Canada\|Research Site, Montreal, Quebec, H2X 0A9, Canada\|Research Site, Montreal, Quebec, H3T 1E2, Canada\|Research Site, Montreal, Quebec, H4A-3J1, Canada\|Research Site, Quebec City, Quebec, G1S 4L8, Canada\|Research Site, Changchun, 130021, China\|Research Site, Hangzhou, 310022, China\|Research Site, Shanghai, 200032, China\|Research Site, Brno, 625 00, Czechia\|Research Site, Brno, 656 53, Czechia\|Research Site, Olomouc, 779 00, Czechia\|Research Site, Ostrava Poruba, 708 52, Czechia\|Research Site, Praha 2, 128 08, Czechia\|Research Site, Praha 5, 150 06, Czechia\|Research Site, Aalborg, 9000, Denmark\|Research Site, Kuopio, 70210, Finland\|Research Site, Lille Cedex, 59020, France\|Research Site, Lyon, 69373, France\|Research Site, Plerin, 22190, France\|Research Site, Villejuif, 94800, France\|Research Site, Dresden, 1307, Germany\|Research Site, Budapest, 1032, Hungary\|Research Site, Budapest, 1122, Hungary\|Research Site, Haifa, 31096, Israel\|Research Site, Jerusalem, 91031, Israel\|Research Site, Jerusalem, 91120, Israel\|Research Site, Petah Tikva, 49100, Israel\|Research Site, Ramat Gan, 5265601, Israel\|Research Site, Tel Aviv, 6423906, Israel\|Research Site, Ancona, 60020, Italy\|Research Site, Bologna, 40138, Italy\|Research Site, Brescia, 25123, Italy\|Research Site, Candiolo, 10060, Italy\|Research Site, Catania, 95126, Italy\|Research Site, Lecce, 73100, Italy\|Research Site, Lecco, 23900, Italy\|Research Site, Milano, 20132, Italy\|Research Site, Milan, 20141, Italy\|Research Site, Napoli, 80131, Italy\|Research Site, Padova, 35128, Italy\|Research Site, Roma, 00168, Italy\|Research Site, Torino, 10128, Italy\|Research Site, Verona, 37134, Italy\|Research Site, Seoul, 01812, Korea, Republic of\|Research Site, Seoul, 03080, Korea, Republic of\|Research Site, Seoul, 03722, Korea, Republic of\|Research Site, Seoul, 06273, Korea, Republic of\|Research Site, Seoul, 06351, Korea, Republic of\|Research Site, Seoul, 6351, Korea, Republic of\|Research Site, Bia?ystok, 15-027, Poland\|Research Site, Grzepnica, 72-003, Poland\|Research Site, Lublin, 20-090, Poland\|Research Site, Olsztyn, 10-561, Poland\|Research Site, Poznan, 61-866, Poland\|Research Site, Poznań, 60-569, Poland\|Research Site, Lisboa, 1649-035, Portugal\|Research Site, Porto, 4200-072, Portugal\|Research Site, Sankt-Peterburg, 197758, Russian Federation\|Research Site, Ljubljana, 1000, Slovenia\|Research Site, Badalona, 08916, Spain\|Research Site, Barcelona, 08035, Spain\|Research Site, Barcelona, 8907, Spain\|Research Site, Barcelona, ?08041, Spain\|Research Site, Cordoba, 14004, Spain\|Research Site, Granada, 18014, Spain\|Research Site, Madrid, 28027, Spain\|Research Site, Madrid, 28041, Spain\|Research Site, Madrid, 28046, Spain\|Research Site, Pamplona, 31008, Spain\|Research Site, San Sebastian, 20014, Spain\|Research Site, Valencia, 46026, Spain\|Research Site, Vigo, 36312, Spain\|Research Site, Zaragoza, 50009, Spain\|Research Site, Lund, 22185, Sweden\|Research Site, Taipei, 112, Taiwan\|Research Site, Ankara, 06230, Turkey\|Research Site, Istanbul, 34093, Turkey\|Research Site, Sahinbey, 27310, Turkey\|Research Site, Birmingham, B18 7QH, United Kingdom\|Research Site, Edinburgh, EH4 2XU, United Kingdom\|Research Site, Glasgow, G12 OYN, United Kingdom\|Research Site, Hull, HU16 5JQ, United Kingdom\|Research Site, London, SW3 6JJ, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom\|Research Site, Taunton, TA1 5DA, United Kingdom Less <<
NCT05262608	Prostate Cancer\|Prostate Carci... More >>noma\|Metastatic Castration-resistant Prostate Cancer Less <<	PHASE2	UNKNOWN	2024-04-26	Sun Yat-sen Memorial Hospital,... More >> Sun Yat-sen University, Guangzhou, China Less <<
NCT03251872	Pulmonary Arterial Hypertensio... More >>n Less <<	EARLY_PHASE1	TERMINATED	2019-12-01	IUCPQ-UL, Quebec City, Quebec,... More >> G1V 4G5, Canada Less <<
NCT03085147	Oral Squamous Cell Carcinoma (... More >>OSCC) Less <<	PHASE1\|PHASE2	RECRUITING	2025-07-26	Memorial Sloan Kettering Baski... More >>ng Ridge (Consent Only), Basking Ridge, New Jersey, 07920, United States\|Memorial Sloan Kettering Monmouth (Consent only), Middletown, New Jersey, 07748, United States\|Memorial Sloan Kettering Bergen (Consent only), Montvale, New Jersey, 07645, United States\|Memorial Sloan Kettering Suffolk-Commack (Consent only), Commack, New York, 11725, United States\|Memorial Sloan Kettering Westchester (Consent Only), Harrison, New York, 10604, United States\|Memorial Sloan Kettering Cancer Center, New York, New York, 10065, United States\|Memorial Sloan Kettering Nassau (Consent only), Rockville Centre, New York, 11553, United States Less <<
NCT04532645	Ovary Cancer		COMPLETED	2024-09-27	Research Site, Avignon Cedex 9... More >>, 84918, France\|Research Site, Besancon, 25000, France\|Research Site, Bordeaux, 33000, France\|Research Site, Bourg-en-Bresse, 1012, France\|Research Site, Calais, 62100, France\|Research Site, Chambray-les-Tours, 37175, France\|Research Site, Epagny Metz-Tessy, 74370, France\|Research Site, Grenoble, 38000, France\|Research Site, Langon, 33210, France\|Research Site, Lyon, 69004, France\|Research Site, Nancy, 54000, France\|Research Site, Paris, 75014, France\|Research Site, Pierre-Benite, 69310, France\|Research Site, Roubaix, 59100, France\|Research Site, Saint-Cloud, 92210, France\|Research Site, Saint-Gregoire, 35760, France\|Research Site, Suresnes, 92150, France\|Research Site, Tours, 37000, France\|Research Site, Villejuif, 94800, France\|Research Site, Acquaviva delle Fonti, 70021, Italy\|Research Site, Aviano, 33081, Italy\|Research Site, Bari, 70124, Italy\|Research Site, Bologna, 40138, Italy\|Research Site, Cagliari, 09121, Italy\|Research Site, Catania, 95126, Italy\|Research Site, Firenze, 50134, Italy\|Research Site, Genova, 16132, Italy\|Research Site, Milano, 20133, Italy\|Research Site, Milano, 20141, Italy\|Research Site, Milano, 20162, Italy\|Research Site, Modena, 41124, Italy\|Research Site, Napoli, 80131, Italy\|Research Site, Negrar, 37024, Italy\|Research Site, Parma, 43126, Italy\|Research Site, Roma, 00144, Italy\|Research Site, Roma, 00168, Italy\|Research Site, Torino, 10128, Italy\|Research Site, Birmingham, United Kingdom\|Research Site, Cambridge, United Kingdom\|Research Site, Ediburgh, United Kingdom\|Research Site, Glasgow, United Kingdom\|Research Site, Guildford, United Kingdom\|Research Site, Leeds, United Kingdom\|Research Site, Liverpool, United Kingdom\|Research Site, London, EC1A7BE, United Kingdom\|Research Site, London, NW12BU, United Kingdom\|Research Site, London, SW36JJ, United Kingdom\|Research Site, London, W120HS, United Kingdom\|Research Site, Maidstone, United Kingdom\|Research Site, Manchester, United Kingdom\|Research Site, Newcastle, United Kingdom\|Research Site, Northampton, United Kingdom\|Research Site, Nottingham, United Kingdom\|Research Site, Portsmouth, United Kingdom\|Research Site, Swansea, United Kingdom Less <<
NCT00777582	Solid Tumors	PHASE1	ACTIVE_NOT_RECRUITING	2025-03-31	Research Site, Randwick, 2031,... More >> Australia\|Research Site, Leuven, 3000, Belgium\|Research Site, Bellinzona, CH-6500, Switzerland\|Research Site, Edinburgh, EH4 2XR, United Kingdom\|Research Site, London, NW1 2PG, United Kingdom\|Research Site, Manchester, M20 4BX, United Kingdom\|Research Site, Newcastle upon Tyne, NE7 7DN, United Kingdom\|Research Site, Northwood, HA6 2RN, United Kingdom\|Research Site, Oxford, OX3 7LE, United Kingdom\|Research Site, Sutton, SM2 5PT, United Kingdom Less <<

CAS No. :	763113-22-0
Formula :	C₂₄H₂₃FN₄O₃
M.W :	434.46
SMILES Code :	O=C1NN=C(CC2=CC=C(F)C(C(N3CCN(C(C4CC4)=O)CC3)=O)=C2)C5=C1C=CC=C5
Synonyms :	AZD2281; KU0059436
MDL No. :	MFCD13185161
InChI Key :	FDLYAMZZIXQODN-UHFFFAOYSA-N
Pubchem ID :	23725625

GHS Pictogram:
Signal Word:	Danger
Hazard Statements:	H301-H372-H360
Precautionary Statements:	P201-P202-P260-P264-P270-P280-P301+P310-P308+P313-P330-P405-P501
Class:	6.1
UN#:	2811
Packing Group:	Ⅲ

UWB1.289 BRCA1-mutant cells	0.1 μM		Evaluate the combination effect of AZD6738 with Olaparib, showing significant enhancement of cell killing in BRCA1-mutant cells.	PMC9359726
UWB1.289 +BRCA1 cells	0.1 μM		Evaluate the combination effect of AZD6738 with Olaparib, showing weaker effect in BRCA1-complemented cells.	PMC9359726
LN229	15 μM	48 h	To evaluate the synergistic inhibitory effect of combined treatment with Olaparib and KPT330 on the growth of GBM cells, the results showed that the combined treatment significantly inhibited cell proliferation.	PMC10813631
T98G	15 μM	48 h	To evaluate the synergistic inhibitory effect of combined treatment with Olaparib and KPT330 on the growth of GBM cells, the results showed that the combined treatment significantly inhibited cell proliferation.	PMC10813631
E0771EGFR vIII cells	1 μM, 5 μM, 10 μM	24 or 48 h	To evaluate the cytotoxicity and DNA damage effects of Olaparib on E0771EGFR vIII cells, results showed that Olaparib significantly increased DNA breaks and inhibited cell proliferation	PMC7791086
4T1EGFR vIII cells	1 μM, 5 μM, 10 μM	24 or 48 h	To evaluate the cytotoxicity and DNA damage effects of Olaparib on 4T1EGFR vIII cells, results showed that Olaparib significantly increased DNA breaks and inhibited cell proliferation	PMC7791086
HepG2 cells	50, 100, 200, 400, 800 μM	24, 48, 72, 96 h	AZD2281 inhibited the proliferation of HepG2 cells in a time- and concentration-dependent manner.	PMC5482153

Mice	BRCA2-mutant TNBC PDX model	Oral	50 mg/kg	5 days-on/2 days-off weekly schedule	Evaluate the antitumor efficacy of AZD6738 in combination with Olaparib, showing complete tumor regression in BRCA2-mutant model.	PMC9359726
NOD-SCID mice	LN229-luc mouse orthotopic xenograft model	Oral	15 mg/kg	Olaparib: daily, KPT330: three times a week	To evaluate the anti-tumor effect of combined treatment with Olaparib and KPT330 in a GBM mouse model, the results showed that the combined treatment significantly prolonged survival and inhibited tumor growth.	PMC10813631
Mice	EGFR vIII-positive tumor xenograft model	Intraperitoneal injection	50 mg/kg	Once daily for 10 days	To evaluate the anti-tumor effects of Olaparib combined with CAR-T cells on EGFR vIII-positive tumors, results showed that Olaparib significantly enhanced the anti-tumor activity of CAR-T cells and reduced MDSC recruitment	PMC7791086
Nude mice	A673 xenograft model	Intraperitoneal (THZ1) and oral (olaparib)	10 mg/kg	Twice daily for 40 days	The combination of THZ1 and olaparib significantly inhibited tumor growth and extended survival without hematopoietic toxicity.	PMC5846483

Precautionary Statements-General
Code	Phrase
P101	If medical advice is needed,have product container or label at hand.
P102	Keep out of reach of children.
P103	Read label before use
Prevention
Code	Phrase
P201	Obtain special instructions before use.
P202	Do not handle until all safety precautions have been read and understood.
P210	Keep away from heat/sparks/open flames/hot surfaces. - No smoking.
P211	Do not spray on an open flame or other ignition source.
P220	Keep/Store away from clothing/combustible materials.
P221	Take any precaution to avoid mixing with combustibles
P222	Do not allow contact with air.
P223	Keep away from any possible contact with water, because of violent reaction and possible flash fire.
P230	Keep wetted
P231	Handle under inert gas.
P232	Protect from moisture.
P233	Keep container tightly closed.
P234	Keep only in original container.
P235	Keep cool
P240	Ground/bond container and receiving equipment.
P241	Use explosion-proof electrical/ventilating/lighting/equipment.
P242	Use only non-sparking tools.
P243	Take precautionary measures against static discharge.
P244	Keep reduction valves free from grease and oil.
P250	Do not subject to grinding/shock/friction.
P251	Pressurized container: Do not pierce or burn, even after use.
P260	Do not breathe dust/fume/gas/mist/vapours/spray.
P261	Avoid breathing dust/fume/gas/mist/vapours/spray.
P262	Do not get in eyes, on skin, or on clothing.
P263	Avoid contact during pregnancy/while nursing.
P264	Wash hands thoroughly after handling.
P265	Wash skin thouroughly after handling.
P270	Do not eat, drink or smoke when using this product.
P271	Use only outdoors or in a well-ventilated area.
P272	Contaminated work clothing should not be allowed out of the workplace.
P273	Avoid release to the environment.
P280	Wear protective gloves/protective clothing/eye protection/face protection.
P281	Use personal protective equipment as required.
P282	Wear cold insulating gloves/face shield/eye protection.
P283	Wear fire/flame resistant/retardant clothing.
P284	Wear respiratory protection.
P285	In case of inadequate ventilation wear respiratory protection.
P231 + P232	Handle under inert gas. Protect from moisture.
P235 + P410	Keep cool. Protect from sunlight.
Response
Code	Phrase
P301	IF SWALLOWED:
P304	IF INHALED:
P305	IF IN EYES:
P306	IF ON CLOTHING:
P307	IF exposed:
P308	IF exposed or concerned:
P309	IF exposed or if you feel unwell:
P310	Immediately call a POISON CENTER or doctor/physician.
P311	Call a POISON CENTER or doctor/physician.
P312	Call a POISON CENTER or doctor/physician if you feel unwell.
P313	Get medical advice/attention.
P314	Get medical advice/attention if you feel unwell.
P315	Get immediate medical advice/attention.
P320
P302 + P352	IF ON SKIN: wash with plenty of soap and water.
P321
P322
P330	Rinse mouth.
P331	Do NOT induce vomiting.
P332	IF SKIN irritation occurs:
P333	If skin irritation or rash occurs:
P334	Immerse in cool water/wrap n wet bandages.
P335	Brush off loose particles from skin.
P336	Thaw frosted parts with lukewarm water. Do not rub affected area.
P337	If eye irritation persists:
P338	Remove contact lenses, if present and easy to do. Continue rinsing.
P340	Remove victim to fresh air and keep at rest in a position comfortable for breathing.
P341	If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P342	If experiencing respiratory symptoms:
P350	Gently wash with plenty of soap and water.
P351	Rinse cautiously with water for several minutes.
P352	Wash with plenty of soap and water.
P353	Rinse skin with water/shower.
P360	Rinse immediately contaminated clothing and skin with plenty of water before removing clothes.
P361	Remove/Take off immediately all contaminated clothing.
P362	Take off contaminated clothing and wash before reuse.
P363	Wash contaminated clothing before reuse.
P370	In case of fire:
P371	In case of major fire and large quantities:
P372	Explosion risk in case of fire.
P373	DO NOT fight fire when fire reaches explosives.
P374	Fight fire with normal precautions from a reasonable distance.
P376	Stop leak if safe to do so. Oxidising gases (section 2.4) 1
P377	Leaking gas fire: Do not extinguish, unless leak can be stopped safely.
P378
P380	Evacuate area.
P381	Eliminate all ignition sources if safe to do so.
P390	Absorb spillage to prevent material damage.
P391	Collect spillage. Hazardous to the aquatic environment
P301 + P310	IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician.
P301 + P312	IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell.
P301 + P330 + P331	IF SWALLOWED: Rinse mouth. Do NOT induce vomiting.
P302 + P334	IF ON SKIN: Immerse in cool water/wrap in wet bandages.
P302 + P350	IF ON SKIN: Gently wash with plenty of soap and water.
P303 + P361 + P353	IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower.
P304 + P312	IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell.
P304 + P340	IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing.
P304 + P341	IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing.
P305 + P351 + P338	IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
P306 + P360	IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes.
P307 + P311	IF exposed: call a POISON CENTER or doctor/physician.
P308 + P313	IF exposed or concerned: Get medical advice/attention.
P309 + P311	IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician.
P332 + P313	IF SKIN irritation occurs: Get medical advice/attention.
P333 + P313	IF SKIN irritation or rash occurs: Get medical advice/attention.
P335 + P334	Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages.
P337 + P313	IF eye irritation persists: Get medical advice/attention.
P342 + P311	IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician.
P370 + P376	In case of fire: Stop leak if safe to Do so.
P370 + P378	In case of fire:
P370 + P380	In case of fire: Evacuate area.
P370 + P380 + P375	In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion.
P371 + P380 + P375	In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion.
Storage
Code	Phrase
P401
P402	Store in a dry place.
P403	Store in a well-ventilated place.
P404	Store in a closed container.
P405	Store locked up.
P406	Store in corrosive resistant/ container with a resistant inner liner.
P407	Maintain air gap between stacks/pallets.
P410	Protect from sunlight.
P411
P412	Do not expose to temperatures exceeding 50 oC/ 122 oF.
P413
P420	Store away from other materials.
P422
P402 + P404	Store in a dry place. Store in a closed container.
P403 + P233	Store in a well-ventilated place. Keep container tightly closed.
P403 + P235	Store in a well-ventilated place. Keep cool.
P410 + P403	Protect from sunlight. Store in a well-ventilated place.
P410 + P412	Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF.
P411 + P235	Keep cool.
Disposal
Code	Phrase
P501	Dispose of contents/container to ...
P502	Refer to manufacturer/supplier for information on recovery/recycling

{[proInfo.proName]}

CAS No.: 763113-22-0

{[proInfo.proName]}

CAS No.: 763113-22-0

Alternative Products

Product Details of Olaparib

Safety of Olaparib

Related Pathways of Olaparib

Isoform Comparison

Biological Activity

Protocol

References

Historical Records

Categories

Precautionary Statements-General

Prevention

Response

Storage

Disposal

Physical hazards

Health hazards

Environmental hazards

Inquiry

Molarity Calculator

Total Compounds Calculator

Dissolution Calculator

Physical hazards
Code	Phrase
H200	Unstable explosive
H201	Explosive; mass explosion hazard
H202	Explosive; severe projection hazard
H203	Explosive; fire, blast or projection hazard
H204	Fire or projection hazard
H205	May mass explode in fire
H220	Extremely flammable gas
H221	Flammable gas
H222	Extremely flammable aerosol
H223	Flammable aerosol
H224	Extremely flammable liquid and vapour
H225	Highly flammable liquid and vapour
H226	Flammable liquid and vapour
H227	Combustible liquid
H228	Flammable solid
H229	Pressurized container: may burst if heated
H230	May react explosively even in the absence of air
H231	May react explosively even in the absence of air at elevated pressure and/or temperature
H240	Heating may cause an explosion
H241	Heating may cause a fire or explosion
H242	Heating may cause a fire
H250	Catches fire spontaneously if exposed to air
H251	Self-heating; may catch fire
H252	Self-heating in large quantities; may catch fire
H260	In contact with water releases flammable gases which may ignite spontaneously
H261	In contact with water releases flammable gas
H270	May cause or intensify fire; oxidizer
H271	May cause fire or explosion; strong oxidizer
H272	May intensify fire; oxidizer
H280	Contains gas under pressure; may explode if heated
H281	Contains refrigerated gas; may cause cryogenic burns or injury
H290	May be corrosive to metals
Health hazards
Code	Phrase
H300	Fatal if swallowed
H301	Toxic if swallowed
H302	Harmful if swallowed
H303	May be harmful if swallowed